score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.R172S	0.427	89.0	0.0	0.0		Putatively Actionable	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Putatively Actionable	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.R172S (Missense)		LIHC_UNION	TCGA-G3-A25T-01A-11D-A16V-10	TCGA-G3-A25T-10A-01D-A16V-10
Putatively Actionable	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.R172K	0.4894	94.0	0.0	0.0		Putatively Actionable	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Putatively Actionable	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.R172K (Missense)		LIHC_UNION	TCGA-ED-A82E-01A-11D-A34Z-10	TCGA-ED-A82E-10A-01D-A34Z-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.1544	136.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	LIHC_UNION	TCGA-DD-AADA-01A-11D-A40R-10	TCGA-DD-AADA-10A-01D-A40U-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.4615	156.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	LIHC_UNION	TCGA-MI-A75C-01A-11D-A32G-10	TCGA-MI-A75C-10A-01D-A32G-10
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.3517	145.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	LIHC_UNION	TCGA-2Y-A9H7-01A-11D-A38X-10	TCGA-2Y-A9H7-10A-01D-A38X-10
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.2745	102.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	LIHC_UNION	TCGA-G3-AAV5-01A-11D-A36X-10	TCGA-G3-AAV5-10A-01D-A370-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4415	342.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	LIHC_UNION	TCGA-CC-5259-01A-31D-A20W-10	TCGA-CC-5259-10A-01D-A20W-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545A	0.4821	390.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545A (Missense)	1	LIHC_UNION	TCGA-ZS-A9CE-01A-11D-A36X-10	TCGA-ZS-A9CE-10A-01D-A370-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.0787	127.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	LIHC_UNION	TCGA-DD-AADI-01A-11D-A40R-10	TCGA-DD-AADI-10A-01D-A40U-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3026	76.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	LIHC_UNION	TCGA-G3-A7M8-01A-11D-A33Q-10	TCGA-G3-A7M8-10A-01D-A33Q-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.4236	144.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	LIHC_UNION	TCGA-DD-AAD0-01A-11D-A40R-10	TCGA-DD-AAD0-10A-01D-A40U-10
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.4327	171.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	LIHC_UNION	TCGA-G3-AAV0-01A-11D-A36X-10	TCGA-G3-AAV0-10A-01D-A370-10
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.K666T	0.4522	115.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K666T (Missense)		LIHC_UNION	TCGA-EP-A26S-01A-11D-A16V-10	TCGA-EP-A26S-10A-01D-A16V-10
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.N626H	0.1161	112.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.N626H (Missense)		LIHC_UNION	TCGA-3K-AAZ8-01A-12D-A38X-10	TCGA-3K-AAZ8-10A-01D-A38X-10
Putatively Actionable			Clinical evidence	Somatic Variant	JAK2	Missense	p.V617F	0.1186	59.0	0.0	0.0																Putatively Actionable	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.V617F (Missense)		LIHC_UNION	TCGA-DD-AADO-01A-11D-A40R-10	TCGA-DD-AADO-10A-01D-A40U-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P411R	0.3621	116.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P411R (Missense)	1	LIHC_UNION	TCGA-DD-A73A-01A-12D-A32G-10	TCGA-DD-A73A-10A-01D-A32G-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.I744V	0.1304	92.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.I744V (Missense)	1	LIHC_UNION	TCGA-DD-AAE3-01A-11D-A40R-10	TCGA-DD-AAE3-10A-01D-A40U-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Insertion	p.A767_V769dup	0.1727	139.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	EGFR exon 20 insertions may predict resistance to TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.A767_V769dup (Insertion)	1	LIHC_UNION	TCGA-DD-AACI-01A-11D-A40R-10	TCGA-DD-AACI-10A-01D-A40U-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Insertion	p.A767_V769dup	0.3333	78.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	EGFR exon 20 insertions may predict resistance to TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.A767_V769dup (Insertion)	1	LIHC_UNION	TCGA-DD-AACY-01A-11D-A40R-10	TCGA-DD-AACY-10A-01D-A40U-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.T1150S	0.3548	124.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.T1150S (Missense)	1	LIHC_UNION	TCGA-DD-A1EK-01A-11D-A20W-10	TCGA-DD-A1EK-10A-01D-A20W-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S1162C	0.0373	268.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S1162C (Missense)	1	LIHC_UNION	TCGA-XR-A8TF-01A-11D-A35Z-10	TCGA-XR-A8TF-10A-01D-A35Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.P141S	0.303	99.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.P141S (Missense)		LIHC_UNION	TCGA-ZP-A9D4-01A-11D-A36X-10	TCGA-ZP-A9D4-10A-01D-A370-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.S197L	0.4048	42.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S197L (Missense)		LIHC_UNION	TCGA-DD-AAVP-01A-11D-A40R-10	TCGA-DD-AAVP-10A-01D-A40U-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.P573Q	0.5833	132.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.P573Q (Missense)		LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D696Y	0.254	63.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D696Y (Missense)		LIHC_UNION	TCGA-UB-AA0U-01A-11D-A382-10	TCGA-UB-AA0U-10A-01D-A385-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.P754S	0.3636	132.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.P754S (Missense)		LIHC_UNION	TCGA-DD-A11D-01A-11D-A12Z-10	TCGA-DD-A11D-11A-12D-A12Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D765G	0.1667	120.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D765G (Missense)		LIHC_UNION	TCGA-CC-A8HT-01A-11D-A35Z-10	TCGA-CC-A8HT-10A-01D-A35Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.T847M	0.7049	61.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.T847M (Missense)		LIHC_UNION	TCGA-DD-AAED-01A-12D-A40R-10	TCGA-DD-AAED-10A-01D-A40U-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.I684S	0.3231	130.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.I684S (Missense)		LIHC_UNION	TCGA-DD-AAEB-01A-11D-A40R-10	TCGA-DD-AAEB-10A-01D-A40U-10
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R200C	0.2093	43.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.R200C (Missense)		LIHC_UNION	TCGA-MI-A75E-01A-11D-A32G-10	TCGA-MI-A75E-10A-01D-A32G-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.T355I	0.4141	128.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.T355I (Missense)	0	LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D444H	0.5098	51.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D444H (Missense)	0	LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E513K	0.0889	45.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E513K (Missense)	0	LIHC_UNION	TCGA-DD-AAW2-01A-11D-A40P-10	TCGA-DD-AAW2-10A-01D-A40P-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L819R	0.4	50.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L819R (Missense)	0	LIHC_UNION	TCGA-CC-A7IH-01A-11D-A33K-10	TCGA-CC-A7IH-10A-01D-A33K-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R981C	0.127	63.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R981C (Missense)	0	LIHC_UNION	TCGA-DD-AAVW-01A-11D-A40R-10	TCGA-DD-AAVW-10A-01D-A40U-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K1001M	0.6364	88.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.K1001M (Missense)	0	LIHC_UNION	TCGA-DD-AACF-01A-11D-A40R-10	TCGA-DD-AACF-10A-01D-A40U-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.K1001N	0.6444	90.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.K1001N (Missense)	0	LIHC_UNION	TCGA-DD-AACF-01A-11D-A40R-10	TCGA-DD-AACF-10A-01D-A40U-10
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S1013G	0.1264	174.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S1013G (Missense)	0	LIHC_UNION	TCGA-CC-A7IG-01A-11D-A33K-10	TCGA-CC-A7IG-10A-01D-A33K-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.R68M	0.2113	142.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.R68M (Missense)	1	LIHC_UNION	TCGA-DD-A4NB-01A-12D-A25V-10	TCGA-DD-A4NB-11A-11D-A25V-10
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.4662	133.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	LIHC_UNION	TCGA-DD-A3A4-01A-11D-A22F-10	TCGA-DD-A3A4-11A-11D-A22F-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.E739*	0.375	112.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.E739* (Nonsense)		LIHC_UNION	TCGA-BC-A10W-01A-11D-A12Z-10	TCGA-BC-A10W-11A-11D-A12Z-10
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2671_splice	0.5556	72.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2671_splice (Splice Site)		LIHC_UNION	TCGA-DD-AADP-01A-11D-A38X-10	TCGA-DD-AADP-10A-01D-A38X-10
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.Y204C	0.1765	34.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.Y204C (Missense)		LIHC_UNION	TCGA-DD-A4NV-01A-11D-A30V-10	TCGA-DD-A4NV-10A-01D-A30V-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.N85S	0.3016	63.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.N85S (Missense)	1	LIHC_UNION	TCGA-DD-AAE3-01A-11D-A40R-10	TCGA-DD-AAE3-10A-01D-A40U-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.A83G	0.3415	82.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.A83G (Missense)	1	LIHC_UNION	TCGA-DD-AAE7-01A-11D-A40R-10	TCGA-DD-AAE7-10A-01D-A40U-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.1094	64.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	LIHC_UNION	TCGA-BW-A5NP-01A-11D-A27I-10	TCGA-BW-A5NP-10A-01D-A27I-10
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.P299T	0.42	100.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.P299T (Missense)		LIHC_UNION	TCGA-WJ-A86L-01A-12D-A45V-10	TCGA-WJ-A86L-10A-01D-A38X-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D201Y	0.254	126.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D201Y (Missense)		LIHC_UNION	TCGA-DD-AACL-01A-11D-A40R-10	TCGA-DD-AACL-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.T417I	0.15	80.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.T417I (Missense)		LIHC_UNION	TCGA-MI-A75G-01A-11D-A32G-10	TCGA-MI-A75G-10A-01D-A32G-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G420V	0.16	75.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G420V (Missense)		LIHC_UNION	TCGA-MI-A75G-01A-11D-A32G-10	TCGA-MI-A75G-10A-01D-A32G-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.N459S	0.266	94.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.N459S (Missense)		LIHC_UNION	TCGA-DD-A118-01A-11D-A12Z-10	TCGA-DD-A118-11A-11D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G1150R	0.2348	132.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G1150R (Missense)		LIHC_UNION	TCGA-DD-AAW0-01A-11D-A40R-10	TCGA-DD-AAW0-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.Q1301H	0.451	51.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.Q1301H (Missense)		LIHC_UNION	TCGA-ED-A7PX-01A-51D-A34Z-10	TCGA-ED-A7PX-10A-01D-A34Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.Q35*	0.2305	243.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.Q35* (Nonsense)		LIHC_UNION	TCGA-DD-A114-01A-11D-A12Z-10	TCGA-DD-A114-10A-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.N133Tfs*49	0.0726	124.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.N133Tfs*49 (Frameshift)		LIHC_UNION	TCGA-CC-A9FV-01A-11D-A36X-10	TCGA-CC-A9FV-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.W304*	0.4483	29.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.W304* (Nonsense)		LIHC_UNION	TCGA-CC-A9FS-01A-11D-A36X-10	TCGA-CC-A9FS-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.E450*	0.746	63.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.E450* (Nonsense)		LIHC_UNION	TCGA-DD-AADL-01A-11D-A40R-10	TCGA-DD-AADL-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.E450*	0.7593	54.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.E450* (Nonsense)		LIHC_UNION	TCGA-DD-AADL-01A-11D-A40R-10	TCGA-DD-AADL-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift		0.4375	32.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2  (Frameshift)		LIHC_UNION	TCGA-MI-A75I-01A-11D-A32G-10	TCGA-MI-A75I-10A-01D-A32G-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.Q794*	0.4667	30.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.Q794* (Nonsense)		LIHC_UNION	TCGA-G3-AAV7-01A-11D-A382-10	TCGA-G3-AAV7-10A-01D-A385-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.A1171Lfs*20	0.1406	64.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.A1171Lfs*20 (Frameshift)		LIHC_UNION	TCGA-DD-A3A6-01A-11D-A22F-10	TCGA-DD-A3A6-11A-11D-A22F-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.Q1395*	0.2308	52.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.Q1395* (Nonsense)		LIHC_UNION	TCGA-DD-A4NH-01A-11D-A27I-10	TCGA-DD-A4NH-10A-01D-A27I-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.N1488Kfs*36	0.3752	717.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.N1488Kfs*36 (Frameshift)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.I1614Hfs*38	0.1077	65.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.I1614Hfs*38 (Frameshift)		LIHC_UNION	TCGA-CC-A9FV-01A-11D-A36X-10	TCGA-CC-A9FV-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.N1651Kfs*48	0.4583	24.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.N1651Kfs*48 (Frameshift)		LIHC_UNION	TCGA-BC-A3KF-01A-11D-A20W-10	TCGA-BC-A3KF-10A-01D-A20W-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Frameshift	p.I1702Sfs*123	0.3548	31.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.I1702Sfs*123 (Frameshift)		LIHC_UNION	TCGA-CC-A7IJ-01A-11D-A33Q-10	TCGA-CC-A7IJ-10A-01D-A33Q-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D982Y	0.3111	90.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D982Y (Missense)		LIHC_UNION	TCGA-ZP-A9CV-01A-11D-A382-10	TCGA-ZP-A9CV-10B-01D-A385-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.V618G	0.2857	63.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.V618G (Missense)	0	LIHC_UNION	TCGA-KR-A7K0-01A-12D-A33Q-10	TCGA-KR-A7K0-10A-01D-A33Q-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.T484A	0.3836	159.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.T484A (Missense)	0	LIHC_UNION	TCGA-G3-A3CK-01A-11D-A20W-10	TCGA-G3-A3CK-10A-01D-A20W-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.T460A	0.2963	135.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.T460A (Missense)	0	LIHC_UNION	TCGA-DD-AAE7-01A-11D-A40R-10	TCGA-DD-AAE7-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R324P	0.5185	27.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R324P (Missense)	0	LIHC_UNION	TCGA-XR-A8TC-01A-11D-A35Z-10	TCGA-XR-A8TC-10A-01D-A35Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y72F	0.2203	286.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y72F (Missense)	0	LIHC_UNION	TCGA-G3-AAV0-01A-11D-A36X-10	TCGA-G3-AAV0-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.M1209Nfs*11	0.7123	73.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M1209Nfs*11 (Frameshift)		LIHC_UNION	TCGA-BC-A10Q-01A-11D-A12Z-10	TCGA-BC-A10Q-11A-11D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R472*	0.5833	96.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R472* (Nonsense)		LIHC_UNION	TCGA-DD-A1EA-01A-11D-A12Z-10	TCGA-DD-A1EA-10A-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R472*	0.0571	140.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R472* (Nonsense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.Y417Ifs*3	0.75	64.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y417Ifs*3 (Frameshift)		LIHC_UNION	TCGA-DD-AADY-01A-11D-A40R-10	TCGA-DD-AADY-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.E422*	0.6512	86.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.E422* (Nonsense)		LIHC_UNION	TCGA-DD-A1EK-01A-11D-A20W-10	TCGA-DD-A1EK-10A-01D-A20W-10
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.T356Pfs*84	0.5745	47.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.T356Pfs*84 (Frameshift)		LIHC_UNION	TCGA-FV-A3R2-01A-11D-A22F-10	TCGA-FV-A3R2-11A-11D-A22F-10
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.Q415H	0.7905	105.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.Q415H (Missense)	0	LIHC_UNION	TCGA-CC-5263-01A-01D-A12Z-10	TCGA-CC-5263-10B-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.Q415H	0.1406	192.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.Q415H (Missense)	0	LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.Q415H	0.7938	97.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.Q415H (Missense)	0	LIHC_UNION	TCGA-CC-5263-01A-01D-A12Z-10	TCGA-CC-5263-10B-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.D592E	0.4892	139.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.D592E (Missense)	0	LIHC_UNION	TCGA-EP-A2KB-01A-11D-A183-10	TCGA-EP-A2KB-10A-01D-A183-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X212_splice	0.7143	14.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X212_splice (Splice Site)	1	LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X212_splice	0.75	16.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X212_splice (Splice Site)	1	LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.G293Efs*14	0.7564	78.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G293Efs*14 (Frameshift)	1	LIHC_UNION	TCGA-QA-A7B7-01A-11D-A32G-10	TCGA-QA-A7B7-10A-01D-A32G-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.G293Efs*14	0.7553	94.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.G293Efs*14 (Frameshift)	1	LIHC_UNION	TCGA-QA-A7B7-01A-11D-A32G-10	TCGA-QA-A7B7-10A-01D-A32G-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.N323Kfs*2	0.6667	138.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N323Kfs*2 (Frameshift)	1	LIHC_UNION	TCGA-BD-A2L6-01A-11D-A20W-10	TCGA-BD-A2L6-11A-21D-A20W-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Y346Sfs*13	0.1316	228.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y346Sfs*13 (Nonsense)	1	LIHC_UNION	TCGA-YA-A8S7-01A-11D-A36X-10	TCGA-YA-A8S7-10A-01D-A370-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.A856D	0.8627	51.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.A856D (Missense)	1	LIHC_UNION	TCGA-CC-A8HS-01A-11D-A35Z-10	TCGA-CC-A8HS-10A-01D-A35Z-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.A856D	0.8409	44.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.A856D (Missense)	1	LIHC_UNION	TCGA-CC-A8HS-01A-11D-A35Z-10	TCGA-CC-A8HS-10A-01D-A35Z-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.Q179R	0.4857	70.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.Q179R (Missense)	1	LIHC_UNION	TCGA-DD-A4NG-01A-11D-A27I-10	TCGA-DD-A4NG-10A-01D-A27I-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.Y130C	0.2941	51.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.Y130C (Missense)	0	LIHC_UNION	TCGA-FV-A3R2-01A-11D-A22F-10	TCGA-FV-A3R2-11A-11D-A22F-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M1478V	0.3119	218.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M1478V (Missense)		LIHC_UNION	TCGA-ED-A459-01A-11D-A25V-10	TCGA-ED-A459-10A-01D-A25V-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G920C	0.4463	354.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G920C (Missense)		LIHC_UNION	TCGA-FV-A2QR-01A-11D-A20W-10	TCGA-FV-A2QR-11A-11D-A20W-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.Y734N	0.0946	74.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Y734N (Missense)		LIHC_UNION	TCGA-DD-AAW1-01A-11D-A40P-10	TCGA-DD-AAW1-10A-01D-A40P-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P650T	0.5912	159.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P650T (Missense)		LIHC_UNION	TCGA-5R-AA1C-01A-11D-A40R-10	TCGA-5R-AA1C-10A-01D-A40U-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.G452W	0.2832	226.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G452W (Missense)		LIHC_UNION	TCGA-G3-AAV6-01A-21D-A36X-10	TCGA-G3-AAV6-10A-01D-A370-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M233I	0.2764	199.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M233I (Missense)		LIHC_UNION	TCGA-DD-A3A5-01A-11D-A22F-10	TCGA-DD-A3A5-11A-11D-A22F-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.A206T	0.0659	182.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.A206T (Missense)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P106S	0.25	24.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P106S (Missense)		LIHC_UNION	TCGA-MI-A75H-01A-11D-A32G-10	TCGA-MI-A75H-10A-01D-A32G-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P27T	0.0935	139.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P27T (Missense)	1	LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P27T	0.473	74.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P27T (Missense)	1	LIHC_UNION	TCGA-G3-A25U-01A-11D-A16V-10	TCGA-G3-A25U-10A-01D-A16V-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R38H	0.2927	164.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R38H (Missense)	1	LIHC_UNION	TCGA-DD-AACM-01A-11D-A40R-10	TCGA-DD-AACM-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.T86S	0.2684	272.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.T86S (Missense)	1	LIHC_UNION	TCGA-DD-AACT-01A-11D-A40R-10	TCGA-DD-AACT-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P471L	0.051	98.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P471L (Missense)	1	LIHC_UNION	TCGA-HP-A5N0-01A-11D-A28X-10	TCGA-HP-A5N0-10A-01D-A28X-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E726K	0.3676	253.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E726K (Missense)	1	LIHC_UNION	TCGA-GJ-A6C0-01A-12D-A30V-10	TCGA-GJ-A6C0-10A-01D-A30V-10
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.T1052K	0.4328	67.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.T1052K (Missense)	1	LIHC_UNION	TCGA-DD-A4NE-01A-11D-A27I-10	TCGA-DD-A4NE-11A-11D-A27I-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P109Afs*6	0.5714	14.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P109Afs*6 (Frameshift)		LIHC_UNION	TCGA-DD-AACG-01A-11D-A40R-10	TCGA-DD-AACG-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A165Gfs*67	0.5	32.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A165Gfs*67 (Frameshift)		LIHC_UNION	TCGA-DD-AADR-01A-11D-A40R-10	TCGA-DD-AADR-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y471Lfs*152	0.56	75.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y471Lfs*152 (Frameshift)		LIHC_UNION	TCGA-DD-AACP-01A-11D-A40R-10	TCGA-DD-AACP-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P728Qfs*87	0.5145	173.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P728Qfs*87 (Frameshift)		LIHC_UNION	TCGA-CC-5258-01A-01D-A12Z-10	TCGA-CC-5258-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P728Qfs*87	0.1179	229.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P728Qfs*87 (Frameshift)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.K1129*	0.3467	75.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K1129* (Nonsense)		LIHC_UNION	TCGA-CC-A9FS-01A-11D-A36X-10	TCGA-CC-A9FS-10A-01D-A370-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.I1130Tfs*28	0.6087	46.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.I1130Tfs*28 (Frameshift)		LIHC_UNION	TCGA-DD-AADP-01A-11D-A38X-10	TCGA-DD-AADP-10A-01D-A38X-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1142*	0.1814	226.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1142* (Nonsense)		LIHC_UNION	TCGA-CC-5262-01A-01D-A12Z-10	TCGA-CC-5262-10B-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1142*	0.4044	183.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1142* (Nonsense)		LIHC_UNION	TCGA-DD-A39W-01A-11D-A20W-10	TCGA-DD-A39W-11A-11D-A20W-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1499*	0.0521	96.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1499* (Nonsense)		LIHC_UNION	TCGA-DD-AAE7-01A-11D-A40R-10	TCGA-DD-AAE7-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1542*	0.6818	44.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1542* (Nonsense)		LIHC_UNION	TCGA-FV-A23B-01A-11D-A16V-10	TCGA-FV-A23B-11A-11D-A16V-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A1687Dfs*2	0.202	99.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A1687Dfs*2 (Frameshift)		LIHC_UNION	TCGA-2V-A95S-01A-11D-A36X-10	TCGA-2V-A95S-10D-01D-A370-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.E1733Gfs*3	0.5455	88.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1733Gfs*3 (Frameshift)		LIHC_UNION	TCGA-DD-A39V-01A-11D-A20W-10	TCGA-DD-A39V-11A-11D-A20W-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1930Qfs*26	0.0841	107.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1930Qfs*26 (Frameshift)		LIHC_UNION	TCGA-KR-A7K8-01A-11D-A33K-10	TCGA-KR-A7K8-10A-01D-A33K-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q1974Tfs*43	0.2826	92.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1974Tfs*43 (Frameshift)		LIHC_UNION	TCGA-BW-A5NQ-01A-11D-A27I-10	TCGA-BW-A5NQ-10A-01D-A27I-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.K2033Rfs*9	0.6705	88.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K2033Rfs*9 (Frameshift)		LIHC_UNION	TCGA-DD-AAVX-01A-11D-A40R-10	TCGA-DD-AAVX-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q2039Hfs*60	0.7988	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q2039Hfs*60 (Frameshift)		LIHC_UNION	TCGA-EP-A2KB-01A-11D-A183-10	TCGA-EP-A2KB-10A-01D-A183-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q2039Hfs*60	0.7581	124.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q2039Hfs*60 (Frameshift)		LIHC_UNION	TCGA-EP-A2KB-01A-11D-A183-10	TCGA-EP-A2KB-10A-01D-A183-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.V2169Cfs*56	0.2	60.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.V2169Cfs*56 (Frameshift)		LIHC_UNION	TCGA-DD-A1EH-01A-11D-A12Z-10	TCGA-DD-A1EH-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.V2228Afs*32	0.4884	43.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.V2228Afs*32 (Frameshift)		LIHC_UNION	TCGA-XR-A8TF-01A-11D-A35Z-10	TCGA-XR-A8TF-10A-01D-A35Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A2234Gfs*34	0.6471	17.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A2234Gfs*34 (Frameshift)		LIHC_UNION	TCGA-CC-A123-01A-11D-A12Z-10	TCGA-CC-A123-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L910P	0.3108	74.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L910P (Missense)		LIHC_UNION	TCGA-DD-AACD-01A-11D-A40R-10	TCGA-DD-AACD-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L910P	0.2202	109.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L910P (Missense)		LIHC_UNION	TCGA-LG-A9QD-01A-11D-A382-10	TCGA-LG-A9QD-10A-01D-A385-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E871D	0.3276	116.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E871D (Missense)		LIHC_UNION	TCGA-ED-A7XP-01A-11D-A34Z-10	TCGA-ED-A7XP-10A-01D-A34Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P815S	0.3235	136.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P815S (Missense)		LIHC_UNION	TCGA-DD-A119-01A-11D-A12Z-10	TCGA-DD-A119-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P815S	0.0592	169.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.P815S (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S729C	0.4331	127.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S729C (Missense)		LIHC_UNION	TCGA-DD-AAD5-01A-11D-A40R-10	TCGA-DD-AAD5-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S729C	0.7527	93.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S729C (Missense)		LIHC_UNION	TCGA-DD-AAVX-01A-11D-A40R-10	TCGA-DD-AAVX-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S703I	0.4677	62.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S703I (Missense)		LIHC_UNION	TCGA-DD-AACY-01A-11D-A40R-10	TCGA-DD-AACY-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.A557V	0.1538	65.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.A557V (Missense)		LIHC_UNION	TCGA-ZP-A9CV-01A-11D-A382-10	TCGA-ZP-A9CV-10B-01D-A385-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.A557S	0.1515	66.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.A557S (Missense)		LIHC_UNION	TCGA-ZP-A9CV-01A-11D-A382-10	TCGA-ZP-A9CV-10B-01D-A385-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.N330Y	0.4225	71.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.N330Y (Missense)		LIHC_UNION	TCGA-DD-AADV-01A-11D-A38X-10	TCGA-DD-AADV-10A-01D-A38X-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E188V	0.2833	120.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E188V (Missense)		LIHC_UNION	TCGA-BD-A3EP-01A-11D-A22F-10	TCGA-BD-A3EP-11A-12D-A22F-10
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.L211F	0.2857	980.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.L211F (Missense)	0	LIHC_UNION	TCGA-DD-AAEB-01A-11D-A40R-10	TCGA-DD-AAEB-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L174R	0.2388	268.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L174R (Missense)	1	LIHC_UNION	TCGA-DD-A4NV-01A-11D-A30V-10	TCGA-DD-A4NV-10A-01D-A30V-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.C219S	0.3684	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.C219S (Missense)	1	LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.3168	202.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	LIHC_UNION	TCGA-DD-AADR-01A-11D-A40R-10	TCGA-DD-AADR-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S681C	0.3953	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S681C (Missense)	1	LIHC_UNION	TCGA-DD-AACJ-01A-11D-A40R-10	TCGA-DD-AACJ-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S867T	0.4688	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S867T (Missense)	1	LIHC_UNION	TCGA-CC-A3MB-01A-11D-A20W-10	TCGA-CC-A3MB-10A-01D-A20W-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R1768G	0.1346	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R1768G (Missense)	1	LIHC_UNION	TCGA-DD-A115-01A-11D-A12Z-10	TCGA-DD-A115-10A-01D-A12Z-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2428T	0.1023	391.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2428T (Missense)	1	LIHC_UNION	TCGA-2Y-A9GW-01A-11D-A382-10	TCGA-2Y-A9GW-10A-01D-A385-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.Q2729H	0.5542	83.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.Q2729H (Missense)	1	LIHC_UNION	TCGA-DD-AAEI-01A-11D-A40R-10	TCGA-DD-AAEI-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2885H	0.4837	246.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2885H (Missense)	1	LIHC_UNION	TCGA-DD-A118-01A-11D-A12Z-10	TCGA-DD-A118-11A-11D-A12Z-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X119_splice	0.75	32.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X119_splice (Splice Site)		LIHC_UNION	TCGA-CC-A5UE-01A-11D-A28X-10	TCGA-CC-A5UE-10A-01D-A28X-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G987S	0.4681	47.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G987S (Missense)	0	LIHC_UNION	TCGA-CC-A7IG-01A-11D-A33K-10	TCGA-CC-A7IG-10A-01D-A33K-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R948C	0.0784	51.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R948C (Missense)	0	LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.S826L	0.1739	184.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.S826L (Missense)	0	LIHC_UNION	TCGA-DD-A4NQ-01A-21D-A28X-10	TCGA-DD-A4NQ-10A-01D-A28X-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R651Q	0.3294	85.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R651Q (Missense)	0	LIHC_UNION	TCGA-DD-AAD6-01A-11D-A40R-10	TCGA-DD-AAD6-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R445Q	0.3889	18.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R445Q (Missense)	0	LIHC_UNION	TCGA-EP-A26S-01A-11D-A16V-10	TCGA-EP-A26S-10A-01D-A16V-10
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.H116N	0.217	212.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.H116N (Missense)	0	LIHC_UNION	TCGA-DD-AACT-01A-11D-A40R-10	TCGA-DD-AACT-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.D324G	0.2716	81.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.D324G (Missense)	0	LIHC_UNION	TCGA-DD-A4NG-01A-11D-A27I-10	TCGA-DD-A4NG-10A-01D-A27I-10
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.H147Y	0.3485	132.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.H147Y (Missense)	0	LIHC_UNION	TCGA-FV-A3R2-01A-11D-A22F-10	TCGA-FV-A3R2-11A-11D-A22F-10
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.Y131C	0.3988	168.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.Y131C (Missense)	0	LIHC_UNION	TCGA-DD-AACW-01A-11D-A40R-10	TCGA-DD-AACW-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.G34C	0.2308	39.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.G34C (Missense)	0	LIHC_UNION	TCGA-CC-A8HT-01A-11D-A35Z-10	TCGA-CC-A8HT-10A-01D-A35Z-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.N679S	0.4624	186.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.N679S (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R309H	0.0374	187.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R309H (Missense)		LIHC_UNION	TCGA-2Y-A9H7-01A-11D-A38X-10	TCGA-2Y-A9H7-10A-01D-A38X-10
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.P298T	0.2982	114.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.P298T (Missense)		LIHC_UNION	TCGA-FV-A4ZQ-01A-11D-A25V-10	TCGA-FV-A4ZQ-10A-01D-A25V-10
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.S22I	0.0638	47.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.S22I (Missense)	0	LIHC_UNION	TCGA-RC-A7SK-01A-11D-A34Z-10	TCGA-RC-A7SK-10A-01D-A34Z-10
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.H1238L	0.4211	133.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.H1238L (Missense)	0	LIHC_UNION	TCGA-DD-AACQ-01A-11D-A40R-10	TCGA-DD-AACQ-10A-01D-A40U-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.N1638I	0.3077	39.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.N1638I (Missense)		LIHC_UNION	TCGA-DD-AAC8-01A-11D-A40R-10	TCGA-DD-AAC8-10A-01D-A40U-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.N875T	0.28	200.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.N875T (Missense)		LIHC_UNION	TCGA-DD-A118-01A-11D-A12Z-10	TCGA-DD-A118-11A-11D-A12Z-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R689W	0.186	129.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R689W (Missense)		LIHC_UNION	TCGA-DD-A1EC-01A-21D-A12Z-10	TCGA-DD-A1EC-11A-11D-A12Z-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.M760I	0.1296	54.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.M760I (Missense)		LIHC_UNION	TCGA-ED-A82E-01A-11D-A34Z-10	TCGA-ED-A82E-10A-01D-A34Z-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R1074Q	0.4539	141.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R1074Q (Missense)		LIHC_UNION	TCGA-DD-AACH-01A-11D-A40R-10	TCGA-DD-AACH-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F341V	0.6827	104.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F341V (Missense)		LIHC_UNION	TCGA-DD-AAD5-01A-11D-A40R-10	TCGA-DD-AAD5-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I332F	0.2533	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I332F (Missense)		LIHC_UNION	TCGA-XR-A8TG-01A-11D-A35Z-10	TCGA-XR-A8TG-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X332_splice	0.4304	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X332_splice (Splice Site)		LIHC_UNION	TCGA-G3-A5SM-01A-12D-A28X-10	TCGA-G3-A5SM-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.T329Rfs*14	0.449	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T329Rfs*14 (Frameshift)		LIHC_UNION	TCGA-DD-AACM-01A-11D-A40R-10	TCGA-DD-AACM-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.F328Sfs*17	0.5902	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F328Sfs*17 (Frameshift)		LIHC_UNION	TCGA-DD-AACE-01A-11D-A40R-10	TCGA-DD-AACE-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.Y327Ffs*18	0.8571	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y327Ffs*18 (Frameshift)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.Q317Lfs*18	0.4118	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317Lfs*18 (Frameshift)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.7778	9.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.7778	9.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.1989	181.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		LIHC_UNION	TCGA-K7-A5RG-01A-11D-A28X-10	TCGA-K7-A5RG-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.5128	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		LIHC_UNION	TCGA-WX-AA44-01A-11D-A38X-10	TCGA-WX-AA44-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.1321	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		LIHC_UNION	TCGA-DD-AADR-01A-11D-A40R-10	TCGA-DD-AADR-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.5385	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		LIHC_UNION	TCGA-FV-A3R2-01A-11D-A22F-10	TCGA-FV-A3R2-11A-11D-A22F-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G302Afs*31	0.3243	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G302Afs*31 (Frameshift)		LIHC_UNION	TCGA-DD-AAE8-01A-11D-A40R-10	TCGA-DD-AAE8-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.K292*	0.4839	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K292* (Nonsense)		LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.62	100.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		LIHC_UNION	TCGA-FV-A4ZP-01A-12D-A25V-10	TCGA-FV-A4ZP-11A-12D-A25V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D281E	0.6333	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D281E (Missense)		LIHC_UNION	TCGA-DD-AACB-01A-11D-A40R-10	TCGA-DD-AACB-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.4848	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		LIHC_UNION	TCGA-ZP-A9D2-01A-11D-A382-10	TCGA-ZP-A9D2-10B-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.C277*	0.7143	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C277* (Nonsense)		LIHC_UNION	TCGA-CC-5263-01A-01D-A12Z-10	TCGA-CC-5263-10B-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.C277*	0.1587	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C277* (Nonsense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A276G	0.9024	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A276G (Missense)		LIHC_UNION	TCGA-BC-A5W4-01A-11D-A28X-10	TCGA-BC-A5W4-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A276G	0.9111	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A276G (Missense)		LIHC_UNION	TCGA-BC-A5W4-01A-11D-A28X-10	TCGA-BC-A5W4-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.A276Lfs*31	0.6275	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A276Lfs*31 (Frameshift)		LIHC_UNION	TCGA-NI-A8LF-01A-11D-A35Z-10	TCGA-NI-A8LF-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.2941	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		LIHC_UNION	TCGA-RG-A7D4-01A-12D-A33Q-10	TCGA-RG-A7D4-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275R	0.169	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275R (Missense)		LIHC_UNION	TCGA-GJ-A3OU-01A-31D-A382-10	TCGA-GJ-A3OU-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.8125	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		LIHC_UNION	TCGA-BC-A217-01A-11D-A152-10	TCGA-BC-A217-10A-01D-A152-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.625	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		LIHC_UNION	TCGA-CC-A8HS-01A-11D-A35Z-10	TCGA-CC-A8HS-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.8846	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		LIHC_UNION	TCGA-BC-A217-01A-11D-A152-10	TCGA-BC-A217-10A-01D-A152-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273S	0.3913	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273S (Missense)		LIHC_UNION	TCGA-DD-AADB-01A-11D-A40R-10	TCGA-DD-AADB-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271V	0.2973	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271V (Missense)		LIHC_UNION	TCGA-DD-AAD3-01A-11D-A40R-10	TCGA-DD-AAD3-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266V	0.507	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266V (Missense)		LIHC_UNION	TCGA-FV-A4ZQ-01A-11D-A25V-10	TCGA-FV-A4ZQ-10A-01D-A25V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266R	0.1071	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266R (Missense)		LIHC_UNION	TCGA-BW-A5NO-01A-11D-A27I-10	TCGA-BW-A5NO-10A-01D-A27I-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.N263Kfs*9	0.4615	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N263Kfs*9 (Frameshift)		LIHC_UNION	TCGA-DD-AACZ-01A-11D-A40R-10	TCGA-DD-AACZ-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.N263Ifs*82	0.4737	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N263Ifs*82 (Frameshift)		LIHC_UNION	TCGA-CC-5258-01A-01D-A12Z-10	TCGA-CC-5258-10A-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G262Vfs*83	0.4127	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G262Vfs*83 (Frameshift)		LIHC_UNION	TCGA-G3-AAV7-01A-11D-A382-10	TCGA-G3-AAV7-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E258K	0.75	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E258K (Missense)		LIHC_UNION	TCGA-RC-A7SB-01A-21D-A34Z-10	TCGA-RC-A7SB-10A-01D-A34Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E258K	0.7619	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E258K (Missense)		LIHC_UNION	TCGA-RC-A7SB-01A-21D-A34Z-10	TCGA-RC-A7SB-10A-01D-A34Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L257P	0.2581	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L257P (Missense)		LIHC_UNION	TCGA-ED-A7XO-01A-11D-A34Z-10	TCGA-ED-A7XO-10A-01D-A34Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.T253A	0.6207	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T253A (Missense)		LIHC_UNION	TCGA-DD-AAE0-01A-11D-A40R-10	TCGA-DD-AAE0-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.I251Sfs*94	0.257	284.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I251Sfs*94 (Frameshift)		LIHC_UNION	TCGA-G3-A25V-01A-11D-A16V-10	TCGA-G3-A25V-10A-01D-A16V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R248Hfs*13	0.8065	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Hfs*13 (Frameshift)		LIHC_UNION	TCGA-ED-A7PZ-01A-11D-A33Q-10	TCGA-ED-A7PZ-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7917	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A5UE-01A-11D-A28X-10	TCGA-CC-A5UE-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7632	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A8HU-01A-11D-A35Z-10	TCGA-CC-A8HU-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7619	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-G3-A25U-01A-11D-A16V-10	TCGA-G3-A25U-10A-01D-A16V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7805	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-QA-A7B7-01A-11D-A32G-10	TCGA-QA-A7B7-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.4615	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-2Y-A9GS-01A-12D-A382-10	TCGA-2Y-A9GS-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.516	188.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A3M9-01A-11D-A20W-10	TCGA-CC-A3M9-10A-01D-A20W-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.75	112.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A3MB-01A-11D-A20W-10	TCGA-CC-A3MB-10A-01D-A20W-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7978	89.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A5UE-01A-11D-A28X-10	TCGA-CC-A5UE-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.4681	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A7II-01A-11D-A33K-10	TCGA-CC-A7II-10A-01D-A33K-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7872	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A8HU-01A-11D-A35Z-10	TCGA-CC-A8HU-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7231	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-CC-A8HV-01A-11D-A35Z-10	TCGA-CC-A8HV-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.2095	148.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-DD-A114-01A-11D-A12Z-10	TCGA-DD-A114-10A-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.5333	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-ED-A7XP-01A-11D-A34Z-10	TCGA-ED-A7XP-10A-01D-A34Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7885	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-G3-A25U-01A-11D-A16V-10	TCGA-G3-A25U-10A-01D-A16V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.7551	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		LIHC_UNION	TCGA-QA-A7B7-01A-11D-A32G-10	TCGA-QA-A7B7-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.9149	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		LIHC_UNION	TCGA-UB-A7MC-01A-11D-A33Q-10	TCGA-UB-A7MC-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.2048	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		LIHC_UNION	TCGA-WQ-AB4B-01A-11D-A40P-10	TCGA-WQ-AB4B-10A-01D-A40P-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.2174	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		LIHC_UNION	TCGA-XR-A8TG-01A-11D-A35Z-10	TCGA-XR-A8TG-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.9333	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		LIHC_UNION	TCGA-UB-A7MC-01A-11D-A33Q-10	TCGA-UB-A7MC-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6818	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		LIHC_UNION	TCGA-BC-A216-01A-11D-A152-10	TCGA-BC-A216-11A-11D-A152-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M246V	0.5758	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M246V (Missense)		LIHC_UNION	TCGA-DD-AACU-01A-11D-A40R-10	TCGA-DD-AACU-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245D	0.596	99.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245D (Missense)		LIHC_UNION	TCGA-2Y-A9H8-01A-11D-A38X-10	TCGA-2Y-A9H8-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238R	0.4138	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238R (Missense)		LIHC_UNION	TCGA-DD-AACL-01A-11D-A40R-10	TCGA-DD-AACL-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.4231	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		LIHC_UNION	TCGA-CC-A8HT-01A-11D-A35Z-10	TCGA-CC-A8HT-10A-01D-A35Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.M237Cfs*10	0.619	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237Cfs*10 (Frameshift)		LIHC_UNION	TCGA-2Y-A9HA-01A-11D-A38X-10	TCGA-2Y-A9HA-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.D228Vfs*18	0.7097	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D228Vfs*18 (Frameshift)		LIHC_UNION	TCGA-DD-AACQ-01A-11D-A40R-10	TCGA-DD-AACQ-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X225_splice	0.9318	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X225_splice (Splice Site)		LIHC_UNION	TCGA-DD-AAD8-01A-11D-A40R-10	TCGA-DD-AAD8-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X225_splice	0.9545	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X225_splice (Splice Site)		LIHC_UNION	TCGA-DD-AAD8-01A-11D-A40R-10	TCGA-DD-AAD8-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E221*	0.7229	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E221* (Nonsense)		LIHC_UNION	TCGA-CC-A7IG-01A-11D-A33K-10	TCGA-CC-A7IG-10A-01D-A33K-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.88	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		LIHC_UNION	TCGA-DD-AADD-01A-11D-A40R-10	TCGA-DD-AADD-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.8889	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		LIHC_UNION	TCGA-DD-AADD-01A-11D-A40R-10	TCGA-DD-AADD-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.4861	144.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		LIHC_UNION	TCGA-ED-A459-01A-11D-A25V-10	TCGA-ED-A459-10A-01D-A25V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S215I	0.4696	115.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S215I (Missense)		LIHC_UNION	TCGA-UB-A7MF-01A-11D-A33K-10	TCGA-UB-A7MF-10A-01D-A33K-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S215N	0.58	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S215N (Missense)		LIHC_UNION	TCGA-G3-A7M6-01A-11D-A33Q-10	TCGA-G3-A7M6-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213L	0.4731	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213L (Missense)		LIHC_UNION	TCGA-2Y-A9GY-01A-11D-A382-10	TCGA-2Y-A9GY-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213Q	0.6235	85.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Q (Missense)		LIHC_UNION	TCGA-BC-A10U-01A-11D-A12Z-10	TCGA-BC-A10U-11A-11D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205C	0.8103	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205C (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205C	0.6907	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205C (Missense)		LIHC_UNION	TCGA-DD-AADL-01A-11D-A40R-10	TCGA-DD-AADL-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205C	0.8194	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205C (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205S	0.3562	146.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205S (Missense)		LIHC_UNION	TCGA-YA-A8S7-01A-11D-A36X-10	TCGA-YA-A8S7-10A-01D-A370-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E204Vfs*4	0.551	98.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204Vfs*4 (Frameshift)		LIHC_UNION	TCGA-DD-AADN-01A-11D-A40R-10	TCGA-DD-AADN-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E204*	0.8113	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204* (Nonsense)		LIHC_UNION	TCGA-WJ-A86L-01A-12D-A45V-10	TCGA-WJ-A86L-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E204*	0.8197	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204* (Nonsense)		LIHC_UNION	TCGA-WJ-A86L-01A-12D-A45V-10	TCGA-WJ-A86L-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V197L	0.7848	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V197L (Missense)		LIHC_UNION	TCGA-RC-A7SH-01A-11D-A382-10	TCGA-RC-A7SH-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V197L	0.7753	89.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V197L (Missense)		LIHC_UNION	TCGA-RC-A7SH-01A-11D-A382-10	TCGA-RC-A7SH-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L194Efs*51	0.4615	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194Efs*51 (Frameshift)		LIHC_UNION	TCGA-G3-A7M9-01A-23D-A34Z-10	TCGA-G3-A7M9-10A-01D-A34Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I195S	0.4957	115.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195S (Missense)		LIHC_UNION	TCGA-DD-AAEA-01A-11D-A40R-10	TCGA-DD-AAEA-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L194R	0.8909	110.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194R (Missense)		LIHC_UNION	TCGA-DD-AAVU-01A-11D-A40R-10	TCGA-DD-AAVU-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.7955	88.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		LIHC_UNION	TCGA-MI-A75G-01A-11D-A32G-10	TCGA-MI-A75G-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.4769	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		LIHC_UNION	TCGA-FV-A3I1-01A-11D-A22F-10	TCGA-FV-A3I1-10A-01D-A22F-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.5763	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		LIHC_UNION	TCGA-G3-A25Z-01A-11D-A16V-10	TCGA-G3-A25Z-10A-01D-A16V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.8137	102.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		LIHC_UNION	TCGA-MI-A75G-01A-11D-A32G-10	TCGA-MI-A75G-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.4095	105.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		LIHC_UNION	TCGA-BW-A5NQ-01A-11D-A27I-10	TCGA-BW-A5NQ-10A-01D-A27I-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.7381	84.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		LIHC_UNION	TCGA-DD-AACG-01A-11D-A40R-10	TCGA-DD-AACG-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.6	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		LIHC_UNION	TCGA-T1-A6J8-01A-11D-A32G-10	TCGA-T1-A6J8-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176W	0.1176	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176W (Missense)		LIHC_UNION	TCGA-DD-AADW-01A-11D-A38X-10	TCGA-DD-AADW-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.4561	114.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R174W	0.6538	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R174W (Missense)		LIHC_UNION	TCGA-RC-A7SK-01A-11D-A34Z-10	TCGA-RC-A7SK-10A-01D-A34Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E171*	0.339	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E171* (Nonsense)		LIHC_UNION	TCGA-DD-A1EI-01A-11D-A12Z-10	TCGA-DD-A1EI-11A-11D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161S	0.1304	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161S (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161S	0.6731	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161S (Missense)		LIHC_UNION	TCGA-DD-A1EL-01A-11D-A152-10	TCGA-DD-A1EL-10A-01D-A152-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.4359	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		LIHC_UNION	TCGA-MI-A75I-01A-11D-A32G-10	TCGA-MI-A75I-10A-01D-A32G-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.7761	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.75	84.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.6129	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		LIHC_UNION	TCGA-CC-A7IJ-01A-11D-A33Q-10	TCGA-CC-A7IJ-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.4327	104.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		LIHC_UNION	TCGA-DD-AAVV-01A-11D-A40R-10	TCGA-DD-AAVV-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R156P	0.3553	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R156P (Missense)		LIHC_UNION	TCGA-K7-AAU7-01A-11D-A382-10	TCGA-K7-AAU7-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V143Rfs*18	0.5	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143Rfs*18 (Frameshift)		LIHC_UNION	TCGA-DD-AACF-01A-11D-A40R-10	TCGA-DD-AACF-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151H	0.2698	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151H (Missense)		LIHC_UNION	TCGA-BD-A3EP-01A-11D-A22F-10	TCGA-BD-A3EP-11A-12D-A22F-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q144*	0.9167	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q144* (Nonsense)		LIHC_UNION	TCGA-DD-AACV-01A-11D-A40R-10	TCGA-DD-AACV-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q144*	0.9114	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q144* (Nonsense)		LIHC_UNION	TCGA-DD-AACV-01A-11D-A40R-10	TCGA-DD-AACV-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V143Afs*29	0.7368	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143Afs*29 (Frameshift)		LIHC_UNION	TCGA-DD-AAE6-01A-11D-A40R-10	TCGA-DD-AAE6-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K139N	0.4783	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K139N (Missense)		LIHC_UNION	TCGA-G3-A5SJ-01A-11D-A27I-10	TCGA-G3-A5SJ-10A-01D-A27I-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q136*	0.5882	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136* (Nonsense)		LIHC_UNION	TCGA-BC-A10R-01A-11D-A12Z-10	TCGA-BC-A10R-11A-11D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.C135*	0.7273	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C135* (Nonsense)		LIHC_UNION	TCGA-DD-A3A7-01A-11D-A22F-10	TCGA-DD-A3A7-11A-11D-A22F-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126D	0.6842	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126D (Missense)		LIHC_UNION	TCGA-DD-A1EB-01A-11D-A12Z-10	TCGA-DD-A1EB-10A-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126N	0.9184	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126N (Missense)		LIHC_UNION	TCGA-DD-AACS-01A-11D-A40R-10	TCGA-DD-AACS-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126N	0.9216	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126N (Missense)		LIHC_UNION	TCGA-DD-AACS-01A-11D-A40R-10	TCGA-DD-AACS-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.1905	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		LIHC_UNION	TCGA-CC-A1HT-01A-11D-A12Z-10	TCGA-CC-A1HT-10A-01D-A12Z-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.5273	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		LIHC_UNION	TCGA-DD-AADC-01A-11D-A40R-10	TCGA-DD-AADC-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.7955	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		LIHC_UNION	TCGA-DD-AAED-01A-12D-A40R-10	TCGA-DD-AAED-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.8421	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		LIHC_UNION	TCGA-DD-AAED-01A-12D-A40R-10	TCGA-DD-AAED-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F113C	0.6063	127.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F113C (Missense)		LIHC_UNION	TCGA-CC-A3MA-01A-11D-A20W-10	TCGA-CC-A3MA-10A-01D-A20W-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S106R	0.7358	106.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S106R (Missense)		LIHC_UNION	TCGA-DD-AADV-01A-11D-A38X-10	TCGA-DD-AADV-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.Y103Tfs*20	0.8462	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y103Tfs*20 (Frameshift)		LIHC_UNION	TCGA-FV-A496-01A-11D-A25V-10	TCGA-FV-A496-10A-01D-A25V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V97Efs*48	0.4627	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V97Efs*48 (Frameshift)		LIHC_UNION	TCGA-BC-A69H-01A-11D-A30V-10	TCGA-BC-A69H-10A-01D-A30V-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S90Pfs*33	0.6364	88.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S90Pfs*33 (Frameshift)		LIHC_UNION	TCGA-2Y-A9H4-01A-11D-A382-10	TCGA-2Y-A9H4-10A-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E56Kfs*67	0.6774	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E56Kfs*67 (Frameshift)		LIHC_UNION	TCGA-DD-AAEI-01A-11D-A40R-10	TCGA-DD-AAEI-10A-01D-A40U-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L43*	0.4407	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L43* (Frameshift)		LIHC_UNION	TCGA-5C-AAPD-01A-21D-A38X-10	TCGA-5C-AAPD-10A-01D-A38X-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X33_splice	0.3226	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X33_splice (Splice Site)		LIHC_UNION	TCGA-UB-A7MD-01A-12D-A34Z-10	TCGA-UB-A7MD-10A-01D-A34Z-10
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.K688N	0.4576	59.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.K688N (Missense)		LIHC_UNION	TCGA-2Y-A9HB-01A-11D-A38X-10	TCGA-2Y-A9HB-10A-01D-A38X-10
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.M150L	0.5	16.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.M150L (Missense)		LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.E77G	0.3091	55.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.E77G (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.A188D	0.319	163.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.A188D (Missense)		LIHC_UNION	TCGA-CC-A8HU-01A-11D-A35Z-10	TCGA-CC-A8HU-10A-01D-A35Z-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.G489R	0.4348	46.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.G489R (Missense)		LIHC_UNION	TCGA-BC-A10Z-01A-11D-A12Z-10	TCGA-BC-A10Z-11A-11D-A12Z-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D601E	0.075	40.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.D601E (Missense)		LIHC_UNION	TCGA-G3-A6UC-01A-21D-A33K-10	TCGA-G3-A6UC-10A-01D-A33K-10
Investigate Actionability			Guideline	Somatic Variant	ETV6	Frameshift	p.S131Hfs*78	0.2521	119.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.S131Hfs*78 (Frameshift)		LIHC_UNION	TCGA-DD-AACZ-01A-11D-A40R-10	TCGA-DD-AACZ-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.F964L	0.0738	149.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.F964L (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E1591Q	0.2764	199.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E1591Q (Missense)		LIHC_UNION	TCGA-KR-A7K7-01A-11D-A33K-10	TCGA-KR-A7K7-10A-01D-A33K-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.E545Q	0.3226	62.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E545Q (Missense)		LIHC_UNION	TCGA-CC-A8HV-01A-11D-A35Z-10	TCGA-CC-A8HV-10A-01D-A35Z-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.C537F	0.4231	52.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.C537F (Missense)		LIHC_UNION	TCGA-CC-A7IL-01A-11D-A33Q-10	TCGA-CC-A7IL-10A-01D-A33Q-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Splice Site	p.X519_splice	0.5938	32.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.X519_splice (Splice Site)		LIHC_UNION	TCGA-CC-A7IL-01A-11D-A33Q-10	TCGA-CC-A7IL-10A-01D-A33Q-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R379H	0.1042	48.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R379H (Missense)		LIHC_UNION	TCGA-2Y-A9HA-01A-11D-A38X-10	TCGA-2Y-A9HA-10A-01D-A38X-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Frameshift	p.Y196Tfs*29	0.395	119.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Y196Tfs*29 (Frameshift)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.A192E	0.3393	112.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.A192E (Missense)		LIHC_UNION	TCGA-2Y-A9HA-01A-11D-A38X-10	TCGA-2Y-A9HA-10A-01D-A38X-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.V1138L	0.3647	255.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.V1138L (Missense)		LIHC_UNION	TCGA-DD-AAEH-01A-11D-A40R-10	TCGA-DD-AAEH-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.K741N	0.1909	241.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K741N (Missense)		LIHC_UNION	TCGA-DD-AAD2-01A-11D-A40R-10	TCGA-DD-AAD2-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.K741Q	0.3558	163.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.K741Q (Missense)		LIHC_UNION	TCGA-MI-A75I-01A-11D-A32G-10	TCGA-MI-A75I-10A-01D-A32G-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A711V	0.4537	313.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A711V (Missense)		LIHC_UNION	TCGA-DD-AADV-01A-11D-A38X-10	TCGA-DD-AADV-10A-01D-A38X-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.V576A	0.2442	86.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.V576A (Missense)		LIHC_UNION	TCGA-EP-A3JL-01A-11D-A20W-10	TCGA-EP-A3JL-10A-01D-A20W-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A433G	0.4237	472.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A433G (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D321V	0.4464	56.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D321V (Missense)		LIHC_UNION	TCGA-DD-AAE3-01A-11D-A40R-10	TCGA-DD-AAE3-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A277S	0.3893	149.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A277S (Missense)		LIHC_UNION	TCGA-G3-AAV1-01A-11D-A382-10	TCGA-G3-AAV1-10A-01D-A385-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.E566*	0.3721	86.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E566* (Nonsense)		LIHC_UNION	TCGA-2Y-A9H7-01A-11D-A38X-10	TCGA-2Y-A9H7-10A-01D-A38X-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.G744Pfs*26	0.1364	66.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.G744Pfs*26 (Frameshift)		LIHC_UNION	TCGA-G3-A25Y-01A-11D-A16V-10	TCGA-G3-A25Y-10A-01D-A16V-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.A1016*	0.3478	69.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.A1016* (Frameshift)		LIHC_UNION	TCGA-CC-A7IH-01A-11D-A33K-10	TCGA-CC-A7IH-10A-01D-A33K-10
Investigate Actionability			Guideline	Somatic Variant	BCOR	Frameshift	p.F1106Lfs*7	0.0561	107.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.F1106Lfs*7 (Frameshift)		LIHC_UNION	TCGA-FV-A495-01A-11D-A25V-10	TCGA-FV-A495-10A-01D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Splice Site	p.X577_splice	0.6282	156.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.X577_splice (Splice Site)		LIHC_UNION	TCGA-2Y-A9HB-01A-11D-A38X-10	TCGA-2Y-A9HB-10A-01D-A38X-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S128C	0.3333	96.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S128C (Missense)		LIHC_UNION	TCGA-5R-AA1C-01A-11D-A40R-10	TCGA-5R-AA1C-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.I559L	0.2703	74.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.I559L (Missense)		LIHC_UNION	TCGA-FV-A4ZQ-01A-11D-A25V-10	TCGA-FV-A4ZQ-10A-01D-A25V-10
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.D1068G	0.3083	133.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.D1068G (Missense)		LIHC_UNION	TCGA-BC-A10W-01A-11D-A12Z-10	TCGA-BC-A10W-11A-11D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.Y1350F	0.3488	324.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.Y1350F (Missense)		LIHC_UNION	TCGA-CC-5259-01A-31D-A20W-10	TCGA-CC-5259-10A-01D-A20W-10
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Frameshift	p.T354Kfs*17	0.087	161.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.T354Kfs*17 (Frameshift)	1	LIHC_UNION	TCGA-ED-A4XI-01A-11D-A25V-10	TCGA-ED-A4XI-10A-01D-A25V-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S384F	0.3684	19.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S384F (Missense)	0	LIHC_UNION	TCGA-DD-A4NL-01A-11D-A28X-10	TCGA-DD-A4NL-11A-11D-A28X-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.T1150Rfs*11	0.0297	236.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T1150Rfs*11 (Frameshift)	0	LIHC_UNION	TCGA-2V-A95S-01A-11D-A36X-10	TCGA-2V-A95S-10D-01D-A370-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H1332Y	0.1967	122.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H1332Y (Missense)	0	LIHC_UNION	TCGA-DD-A1EC-01A-21D-A12Z-10	TCGA-DD-A1EC-11A-11D-A12Z-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.A1996G	0.3704	54.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.A1996G (Missense)	0	LIHC_UNION	TCGA-FV-A4ZP-01A-12D-A25V-10	TCGA-FV-A4ZP-11A-12D-A25V-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H2074D	0.4086	93.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H2074D (Missense)	0	LIHC_UNION	TCGA-BC-A10Y-01A-11D-A12Z-10	TCGA-BC-A10Y-11A-11D-A12Z-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S2559P	0.1154	26.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S2559P (Missense)	0	LIHC_UNION	TCGA-G3-A25S-01A-11D-A16V-10	TCGA-G3-A25S-10A-01D-A16V-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Y2624N	0.1965	173.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Y2624N (Missense)	0	LIHC_UNION	TCGA-ZP-A9CY-01A-11D-A382-10	TCGA-ZP-A9CY-10B-01D-A385-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Y2726C	0.3962	159.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Y2726C (Missense)	0	LIHC_UNION	TCGA-FV-A2QR-01A-11D-A20W-10	TCGA-FV-A2QR-11A-11D-A20W-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Deletion	p.D2995_Y2997del	0.2967	182.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D2995_Y2997del (Deletion)	0	LIHC_UNION	TCGA-FV-A2QR-01A-11D-A20W-10	TCGA-FV-A2QR-11A-11D-A20W-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F3298C	0.0606	99.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F3298C (Missense)	0	LIHC_UNION	TCGA-BD-A3ER-01A-11D-A20W-10	TCGA-BD-A3ER-11A-11D-A20W-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.C1768Y	0.3448	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.C1768Y (Missense)	1	LIHC_UNION	TCGA-DD-A39V-01A-11D-A20W-10	TCGA-DD-A39V-11A-11D-A20W-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.G1471R	0.4054	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.G1471R (Missense)	1	LIHC_UNION	TCGA-FV-A23B-01A-11D-A16V-10	TCGA-FV-A23B-11A-11D-A16V-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.A675G	0.172	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.A675G (Missense)	1	LIHC_UNION	TCGA-DD-AAD1-01A-11D-A40R-10	TCGA-DD-AAD1-10A-01D-A40U-10
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.M658V	0.3529	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.M658V (Missense)	1	LIHC_UNION	TCGA-DD-AAVZ-01A-11D-A40R-10	TCGA-DD-AAVZ-10A-01D-A40U-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Frameshift	p.N367Qfs*113	0.2564	39.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	1	Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH2 p.N367Qfs*113 (Frameshift)		LIHC_UNION	TCGA-2Y-A9H3-01A-11D-A382-10	TCGA-2Y-A9H3-10A-01D-A385-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.C297S	0.36	50.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.C297S (Missense)		LIHC_UNION	TCGA-UB-AA0U-01A-11D-A382-10	TCGA-UB-AA0U-10A-01D-A385-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.Q198P	0.2182	55.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.Q198P (Missense)		LIHC_UNION	TCGA-DD-AAVV-01A-11D-A40R-10	TCGA-DD-AAVV-10A-01D-A40U-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.M182V	0.2486	181.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.M182V (Missense)		LIHC_UNION	TCGA-CC-5262-01A-01D-A12Z-10	TCGA-CC-5262-10B-01D-A12Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.N171T	0.2407	108.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.N171T (Missense)		LIHC_UNION	TCGA-DD-AADL-01A-11D-A40R-10	TCGA-DD-AADL-10A-01D-A40U-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.4866	187.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		LIHC_UNION	TCGA-BC-A10Q-01A-11D-A12Z-10	TCGA-BC-A10Q-11A-11D-A12Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.3053	262.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		LIHC_UNION	TCGA-CC-5260-01A-01D-A12Z-10	TCGA-CC-5260-10B-01D-A12Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132G	0.4607	178.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132G (Missense)		LIHC_UNION	TCGA-DD-A4NA-01A-11D-A25V-10	TCGA-DD-A4NA-11A-11D-A25V-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Nonsense	p.S197*	0.4521	73.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S197* (Nonsense)	0	LIHC_UNION	TCGA-CC-A7IH-01A-11D-A33K-10	TCGA-CC-A7IH-10A-01D-A33K-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Nonsense	p.C809*	0.2152	79.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.C809* (Nonsense)	0	LIHC_UNION	TCGA-CC-5264-01A-01D-A12Z-10	TCGA-CC-5264-10A-01D-A12Z-10
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Splice Site	p.X935_splice	0.4545	66.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.X935_splice (Splice Site)	0	LIHC_UNION	TCGA-DD-A73D-01A-12D-A32G-10	TCGA-DD-A73D-10A-01D-A32G-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Frameshift	p.D8Rfs*22	0.1679	137.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.D8Rfs*22 (Frameshift)	1	LIHC_UNION	TCGA-3K-AAZ8-01A-12D-A38X-10	TCGA-3K-AAZ8-10A-01D-A38X-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.T279I	0.2	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.T279I (Missense)	1	LIHC_UNION	TCGA-CC-A9FW-01A-11D-A36X-10	TCGA-CC-A9FW-10A-01D-A370-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.R322H	0.4247	146.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.R322H (Missense)	1	LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Nonsense	p.K337*	0.507	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.K337* (Nonsense)	1	LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P405T	0.2174	23.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P405T (Missense)	0	LIHC_UNION	TCGA-DD-A4NQ-01A-21D-A28X-10	TCGA-DD-A4NQ-10A-01D-A28X-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.A152D	0.2326	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.A152D (Missense)	0	LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.V132I	0.3509	57.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.V132I (Missense)	0	LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S913A	0.1782	174.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S913A (Missense)	1	LIHC_UNION	TCGA-2Y-A9H3-01A-11D-A382-10	TCGA-2Y-A9H3-10A-01D-A385-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.X794_splice	0.4324	37.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.X794_splice (Splice Site)	1	LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.N604S	0.3241	253.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.N604S (Missense)	1	LIHC_UNION	TCGA-DD-AAD3-01A-11D-A40R-10	TCGA-DD-AAD3-10A-01D-A40U-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P530L	0.4521	73.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P530L (Missense)	0	LIHC_UNION	TCGA-PD-A5DF-01A-11D-A27I-10	TCGA-PD-A5DF-10A-01D-A27I-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.S151N	0.1538	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.S151N (Missense)	0	LIHC_UNION	TCGA-EP-A3JL-01A-11D-A20W-10	TCGA-EP-A3JL-10A-01D-A20W-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.E81A	0.2121	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.E81A (Missense)	0	LIHC_UNION	TCGA-G3-A7M5-01A-11D-A33Q-10	TCGA-G3-A7M5-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.S24C	0.3596	89.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.S24C (Missense)	0	LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.R3Q	0.3704	54.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.R3Q (Missense)	0	LIHC_UNION	TCGA-ZP-A9D1-01A-11D-A382-10	TCGA-ZP-A9D1-10B-01D-A385-10
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Frameshift	p.N130Ifs*9	0.2373	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.N130Ifs*9 (Frameshift)	0	LIHC_UNION	TCGA-2Y-A9H6-01A-11D-A38X-10	TCGA-2Y-A9H6-10A-01D-A38X-10
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.T260A	0.4419	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.T260A (Missense)	0	LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R139W	0.3158	76.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R139W (Missense)		LIHC_UNION	TCGA-DD-AACL-01A-11D-A40R-10	TCGA-DD-AACL-10A-01D-A40U-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Deletion	p.Y1593_L1594del	0.2	150.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.Y1593_L1594del (Deletion)		LIHC_UNION	TCGA-DD-A4NQ-01A-21D-A28X-10	TCGA-DD-A4NQ-10A-01D-A28X-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.A284V	0.1287	101.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.A284V (Missense)	0	LIHC_UNION	TCGA-DD-A4ND-01A-11D-A25V-10	TCGA-DD-A4ND-11A-11D-A25V-10
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.Y295C	0.3241	108.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Y295C (Missense)	0	LIHC_UNION	TCGA-WX-AA44-01A-11D-A38X-10	TCGA-WX-AA44-10A-01D-A38X-10
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.M74V	0.0359	195.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.M74V (Missense)	0	LIHC_UNION	TCGA-ED-A4XI-01A-11D-A25V-10	TCGA-ED-A4XI-10A-01D-A25V-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.M736V	0.8108	37.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.M736V (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.M736V	0.8222	45.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.M736V (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.K722N	0.3947	76.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.K722N (Missense)		LIHC_UNION	TCGA-EP-A2KA-01A-11D-A183-10	TCGA-EP-A2KA-10A-01D-A183-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.V610A	0.0671	149.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.V610A (Missense)		LIHC_UNION	TCGA-KR-A7K8-01A-11D-A33K-10	TCGA-KR-A7K8-10A-01D-A33K-10
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.P196L	0.6364	44.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.P196L (Missense)		LIHC_UNION	TCGA-ED-A7PX-01A-51D-A34Z-10	TCGA-ED-A7PX-10A-01D-A34Z-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Insertion	p.P23dup	0.2857	35.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P23dup (Insertion)		LIHC_UNION	TCGA-CC-A3M9-01A-11D-A20W-10	TCGA-CC-A3M9-10A-01D-A20W-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.I24Hfs*19	0.3111	45.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.I24Hfs*19 (Frameshift)		LIHC_UNION	TCGA-CC-A3M9-01A-11D-A20W-10	TCGA-CC-A3M9-10A-01D-A20W-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Frameshift	p.I24Qfs*26	0.2955	44.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.I24Qfs*26 (Frameshift)		LIHC_UNION	TCGA-CC-A3M9-01A-11D-A20W-10	TCGA-CC-A3M9-10A-01D-A20W-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.H169L	0.2899	138.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.H169L (Missense)		LIHC_UNION	TCGA-EP-A2KA-01A-11D-A183-10	TCGA-EP-A2KA-10A-01D-A183-10
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.R1201C	0.3175	63.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.R1201C (Missense)		LIHC_UNION	TCGA-2Y-A9H7-01A-11D-A38X-10	TCGA-2Y-A9H7-10A-01D-A38X-10
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Splice Site	p.X38_splice	0.6379	58.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.X38_splice (Splice Site)	1	LIHC_UNION	TCGA-DD-AACE-01A-11D-A40R-10	TCGA-DD-AACE-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.G431D	0.2358	123.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.G431D (Missense)	0	LIHC_UNION	TCGA-DD-AAD1-01A-11D-A40R-10	TCGA-DD-AAD1-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.R412S	0.373	126.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.R412S (Missense)	0	LIHC_UNION	TCGA-ZP-A9D1-01A-11D-A382-10	TCGA-ZP-A9D1-10B-01D-A385-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Frameshift	p.E160Sfs*13	0.5333	45.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.E160Sfs*13 (Frameshift)	0	LIHC_UNION	TCGA-DD-A11D-01A-11D-A12Z-10	TCGA-DD-A11D-11A-12D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Frameshift	p.H106Lfs*12	0.5667	30.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.H106Lfs*12 (Frameshift)	0	LIHC_UNION	TCGA-DD-A4NN-01A-11D-A28X-10	TCGA-DD-A4NN-10A-01D-A28X-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.H106Y	0.697	33.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.H106Y (Missense)	0	LIHC_UNION	TCGA-DD-A4NN-01A-11D-A28X-10	TCGA-DD-A4NN-10A-01D-A28X-10
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.K114*	0.1094	128.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.K114* (Nonsense)		LIHC_UNION	TCGA-CC-A5UC-01A-11D-A28X-10	TCGA-CC-A5UC-10A-01D-A28X-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.I1366*	0.2471	85.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.I1366* (Frameshift)		LIHC_UNION	TCGA-DD-AACM-01A-11D-A40R-10	TCGA-DD-AACM-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.E1234V	0.2456	57.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E1234V (Missense)		LIHC_UNION	TCGA-DD-AADG-01A-11D-A40R-10	TCGA-DD-AADG-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.I1200V	0.3704	54.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.I1200V (Missense)		LIHC_UNION	TCGA-ED-A7PZ-01A-11D-A33Q-10	TCGA-ED-A7PZ-10A-01D-A33Q-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.G996Efs*10	0.2375	240.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.G996Efs*10 (Frameshift)		LIHC_UNION	TCGA-DD-A113-01A-11D-A12Z-10	TCGA-DD-A113-10A-01D-A12Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Frameshift	p.S801*	0.1717	99.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S801* (Frameshift)		LIHC_UNION	TCGA-G3-A3CG-01A-11D-A20W-10	TCGA-G3-A3CG-10A-01D-A20W-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.P718A	0.2696	115.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.P718A (Missense)		LIHC_UNION	TCGA-3K-AAZ8-01A-12D-A38X-10	TCGA-3K-AAZ8-10A-01D-A38X-10
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.R297W	0.2778	54.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.R297W (Missense)		LIHC_UNION	TCGA-CC-A5UE-01A-11D-A28X-10	TCGA-CC-A5UE-10A-01D-A28X-10
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Deletion	p.F157del	0.629	62.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.F157del (Deletion)		LIHC_UNION	TCGA-DD-AACX-01A-11D-A40R-10	TCGA-DD-AACX-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Deletion	p.D864_C873delinsG	0.142	169.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.D864_C873delinsG (Deletion)		LIHC_UNION	TCGA-DD-A1E9-01A-21D-A152-10	TCGA-DD-A1E9-11A-11D-A152-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Frameshift	p.A53Gfs*23	0.1481	81.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.A53Gfs*23 (Frameshift)		LIHC_UNION	TCGA-DD-AACC-01A-11D-A40R-10	TCGA-DD-AACC-10A-01D-A40U-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.K145*	0.4367	158.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.K145* (Nonsense)		LIHC_UNION	TCGA-2Y-A9H9-01A-21D-A38X-10	TCGA-2Y-A9H9-10A-01D-A38X-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.Y642C	0.4706	34.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.Y642C (Missense)		LIHC_UNION	TCGA-RC-A7SK-01A-11D-A34Z-10	TCGA-RC-A7SK-10A-01D-A34Z-10
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.I725V	0.4221	154.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.I725V (Missense)		LIHC_UNION	TCGA-DD-AAW2-01A-11D-A40P-10	TCGA-DD-AAW2-10A-01D-A40P-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y1610H	0.7838	37.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1610H (Missense)		LIHC_UNION	TCGA-FV-A3I0-01A-11D-A22F-10	TCGA-FV-A3I0-11A-11D-A22F-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Y1610H	0.7941	34.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Y1610H (Missense)		LIHC_UNION	TCGA-FV-A3I0-01A-11D-A22F-10	TCGA-FV-A3I0-11A-11D-A22F-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S1377A	0.3926	135.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S1377A (Missense)		LIHC_UNION	TCGA-DD-AADP-01A-11D-A38X-10	TCGA-DD-AADP-10A-01D-A38X-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1287K	0.6944	36.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1287K (Missense)		LIHC_UNION	TCGA-LG-A9QC-01A-11D-A36X-10	TCGA-LG-A9QC-10A-01D-A370-10
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.T1247I	0.4412	68.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.T1247I (Missense)		LIHC_UNION	TCGA-G3-A6UC-01A-21D-A33K-10	TCGA-G3-A6UC-10A-01D-A33K-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.H61L	0.4079	1287.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.H61L (Missense)	1	LIHC_UNION	TCGA-DD-AAW3-01A-11D-A40P-10	TCGA-DD-AAW3-10A-01D-A40P-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Deletion	p.T232_R233del	0.4412	68.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.T232_R233del (Deletion)	1	LIHC_UNION	TCGA-DD-AAE2-01A-11D-A40R-10	TCGA-DD-AAE2-10A-01D-A40U-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P246R	0.7842	139.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P246R (Missense)	1	LIHC_UNION	TCGA-DD-A4NE-01A-11D-A27I-10	TCGA-DD-A4NE-11A-11D-A27I-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.P246R	0.8	100.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.P246R (Missense)	1	LIHC_UNION	TCGA-DD-A4NE-01A-11D-A27I-10	TCGA-DD-A4NE-11A-11D-A27I-10
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.K342N	0.8613	137.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.K342N (Missense)	1	LIHC_UNION	TCGA-DD-AAD0-01A-11D-A40R-10	TCGA-DD-AAD0-10A-01D-A40U-10
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Splice Site	p.X685_splice	0.56	50.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.X685_splice (Splice Site)	0	LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Frameshift	p.G1202Efs*56	0.4615	78.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.G1202Efs*56 (Frameshift)		LIHC_UNION	TCGA-BC-A10Z-01A-11D-A12Z-10	TCGA-BC-A10Z-11A-11D-A12Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P136T	0.2632	19.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P136T (Missense)		LIHC_UNION	TCGA-DD-AAEG-01A-11D-A38X-10	TCGA-DD-AAEG-10A-01D-A38X-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1001C	0.4776	67.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1001C (Missense)		LIHC_UNION	TCGA-UB-A7ME-01A-11D-A33K-10	TCGA-UB-A7ME-10A-01D-A33K-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Y1027C	0.2775	209.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y1027C (Missense)		LIHC_UNION	TCGA-ES-A2HT-01A-12D-A183-10	TCGA-ES-A2HT-11A-11D-A183-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.N1475T	0.2037	54.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.N1475T (Missense)		LIHC_UNION	TCGA-DD-A4NR-01A-11D-A30V-10	TCGA-DD-A4NR-10A-01D-A30V-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1665_splice	0.6552	29.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1665_splice (Splice Site)		LIHC_UNION	TCGA-LG-A6GG-01A-11D-A30V-10	TCGA-LG-A6GG-10A-01D-A30V-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Deletion	p.L1681_D1689delinsH	0.1288	163.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L1681_D1689delinsH (Deletion)		LIHC_UNION	TCGA-G3-A3CG-01A-11D-A20W-10	TCGA-G3-A3CG-10A-01D-A20W-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.K2025E	0.6744	86.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K2025E (Missense)		LIHC_UNION	TCGA-DD-AAVX-01A-11D-A40R-10	TCGA-DD-AAVX-10A-01D-A40U-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S2068W	0.4474	38.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S2068W (Missense)		LIHC_UNION	TCGA-UB-A7MD-01A-12D-A34Z-10	TCGA-UB-A7MD-10A-01D-A34Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G2087E	0.2727	99.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G2087E (Missense)		LIHC_UNION	TCGA-ZS-A9CD-01A-11D-A36X-10	TCGA-ZS-A9CD-10A-01D-A370-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S2214C	0.4353	85.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S2214C (Missense)		LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R2236S	0.7857	28.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2236S (Missense)		LIHC_UNION	TCGA-XR-A8TF-01A-11D-A35Z-10	TCGA-XR-A8TF-10A-01D-A35Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R2236S	0.7931	29.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2236S (Missense)		LIHC_UNION	TCGA-XR-A8TF-01A-11D-A35Z-10	TCGA-XR-A8TF-10A-01D-A35Z-10
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.I143Dfs*9	0.2917	48.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.I143Dfs*9 (Frameshift)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Frameshift	p.V162Lfs*15	0.44	50.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.V162Lfs*15 (Frameshift)	0	LIHC_UNION	TCGA-DD-A4NH-01A-11D-A27I-10	TCGA-DD-A4NH-10A-01D-A27I-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K443Q	0.3529	85.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K443Q (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G911S	0.3455	55.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G911S (Missense)		LIHC_UNION	TCGA-ED-A66Y-01A-11D-A30V-10	TCGA-ED-A66Y-10A-01D-A30V-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1068V	0.1099	91.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1068V (Missense)		LIHC_UNION	TCGA-MI-A75G-01A-11D-A32G-10	TCGA-MI-A75G-10A-01D-A32G-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1114N	0.1746	126.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1114N (Missense)		LIHC_UNION	TCGA-UB-AA0U-01A-11D-A382-10	TCGA-UB-AA0U-10A-01D-A385-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1160E	0.1944	72.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1160E (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1160E	0.5686	51.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1160E (Missense)		LIHC_UNION	TCGA-DD-A1EF-01A-11D-A12Z-10	TCGA-DD-A1EF-10A-01D-A12Z-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.L1184P	0.4286	126.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.L1184P (Missense)		LIHC_UNION	TCGA-DD-AADQ-01A-11D-A40R-10	TCGA-DD-AADQ-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.4722	144.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		LIHC_UNION	TCGA-DD-AACZ-01A-11D-A40R-10	TCGA-DD-AACZ-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192H	0.2388	67.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192H (Missense)		LIHC_UNION	TCGA-BC-A10R-01A-11D-A12Z-10	TCGA-BC-A10R-11A-11D-A12Z-10
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K1386N	0.3302	106.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K1386N (Missense)		LIHC_UNION	TCGA-DD-AADN-01A-11D-A40R-10	TCGA-DD-AADN-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.V493A	0.1347	245.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.V493A (Missense)	0	LIHC_UNION	TCGA-CC-A1HT-01A-11D-A12Z-10	TCGA-CC-A1HT-10A-01D-A12Z-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R153C	0.3012	83.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R153C (Missense)	0	LIHC_UNION	TCGA-DD-AAC8-01A-11D-A40R-10	TCGA-DD-AAC8-10A-01D-A40U-10
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R48L	0.2143	364.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R48L (Missense)	0	LIHC_UNION	TCGA-DD-AADK-01A-11D-A40R-10	TCGA-DD-AADK-10A-01D-A40U-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X1482_splice	0.0897	78.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X1482_splice (Splice Site)		LIHC_UNION	TCGA-DD-AADI-01A-11D-A40R-10	TCGA-DD-AADI-10A-01D-A40U-10
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Frameshift	p.P116Hfs*53	0.4	60.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.P116Hfs*53 (Frameshift)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.Q317_E326del	0.7826	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317_E326del (Deletion)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.T230_T231del	0.6538	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T230_T231del (Deletion)		LIHC_UNION	TCGA-BC-A8YO-01A-11D-A36X-10	TCGA-BC-A8YO-10A-01D-A370-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.P191del	0.6986	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P191del (Deletion)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Insertion	p.V157_R158dup	0.6452	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157_R158dup (Insertion)		LIHC_UNION	TCGA-DD-A11A-01A-11D-A12Z-10	TCGA-DD-A11A-10A-01D-A12Z-10
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Nonsense	p.E328Lfs*2	0.1489	47.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.E328Lfs*2 (Nonsense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Nonsense	p.E328Lfs*2	0.7	20.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.E328Lfs*2 (Nonsense)		LIHC_UNION	TCGA-G3-A25S-01A-11D-A16V-10	TCGA-G3-A25S-10A-01D-A16V-10
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.V915A	0.3768	69.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.V915A (Missense)		LIHC_UNION	TCGA-DD-AACJ-01A-11D-A40R-10	TCGA-DD-AACJ-10A-01D-A40U-10
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.L1168V	0.28	25.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.L1168V (Missense)		LIHC_UNION	TCGA-EP-A3RK-01A-11D-A22F-10	TCGA-EP-A3RK-10A-01D-A22F-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Nonsense	p.Y43*	0.4035	57.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.Y43* (Nonsense)		LIHC_UNION	TCGA-CC-A7II-01A-11D-A33K-10	TCGA-CC-A7II-10A-01D-A33K-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.R394C	0.2647	68.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.R394C (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Splice Site	p.X457_splice	0.2703	37.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.X457_splice (Splice Site)		LIHC_UNION	TCGA-G3-A7M7-01A-12D-A34Z-10	TCGA-G3-A7M7-10A-01D-A34Z-10
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.D484G	0.2381	63.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.D484G (Missense)		LIHC_UNION	TCGA-DD-AACI-01A-11D-A40R-10	TCGA-DD-AACI-10A-01D-A40U-10
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Frameshift	p.S176Lfs*4	0.1324	68.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S176Lfs*4 (Frameshift)		LIHC_UNION	TCGA-DD-A4NR-01A-11D-A30V-10	TCGA-DD-A4NR-10A-01D-A30V-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E82D	0.4237	118.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E82D (Missense)		LIHC_UNION	TCGA-DD-A39V-01A-11D-A20W-10	TCGA-DD-A39V-11A-11D-A20W-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E82G	0.5091	55.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E82G (Missense)		LIHC_UNION	TCGA-DD-AAC8-01A-11D-A40R-10	TCGA-DD-AAC8-10A-01D-A40U-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81A	0.2353	68.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81A (Missense)		LIHC_UNION	TCGA-G3-AAV3-01A-11D-A36X-10	TCGA-G3-AAV3-10A-01D-A370-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81C	0.4568	81.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81C (Missense)		LIHC_UNION	TCGA-DD-AADJ-01A-11D-A40R-10	TCGA-DD-AADJ-10A-01D-A40U-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81R	0.54	50.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81R (Missense)		LIHC_UNION	TCGA-DD-AAVY-01A-11D-A40R-10	TCGA-DD-AAVY-10A-01D-A40U-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.T80I	0.3158	76.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.T80I (Missense)		LIHC_UNION	TCGA-5R-AAAM-01A-12D-A40R-10	TCGA-5R-AAAM-10A-01D-A40U-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79V	0.4	60.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79V (Missense)		LIHC_UNION	TCGA-DD-A4NO-01A-11D-A28X-10	TCGA-DD-A4NO-10A-01D-A28X-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Nonsense	p.E79*	0.4167	60.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79* (Nonsense)		LIHC_UNION	TCGA-DD-A4NO-01A-11D-A28X-10	TCGA-DD-A4NO-10A-01D-A28X-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.Q61H	0.3088	68.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.Q61H (Missense)		LIHC_UNION	TCGA-DD-AAVU-01A-11D-A40R-10	TCGA-DD-AAVU-10A-01D-A40U-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Deletion	p.W24_D29delinsY	0.6171	175.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.W24_D29delinsY (Deletion)		LIHC_UNION	TCGA-FV-A3I1-01A-11D-A22F-10	TCGA-FV-A3I1-10A-01D-A22F-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.I28M	0.2037	54.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.I28M (Missense)		LIHC_UNION	TCGA-DD-AAVS-01A-11D-A40R-10	TCGA-DD-AAVS-10A-01D-A40U-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Deletion	p.I28del	0.3043	92.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.I28del (Deletion)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D27Y	0.45	40.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D27Y (Missense)		LIHC_UNION	TCGA-DD-AAEH-01A-11D-A40R-10	TCGA-DD-AAEH-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.Y279C	0.4432	273.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.Y279C (Missense)		LIHC_UNION	TCGA-MI-A75G-01A-11D-A32G-10	TCGA-MI-A75G-10A-01D-A32G-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.A461S	0.2105	57.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.A461S (Missense)		LIHC_UNION	TCGA-CC-A8HT-01A-11D-A35Z-10	TCGA-CC-A8HT-10A-01D-A35Z-10
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.S576I	0.4247	478.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.S576I (Missense)		LIHC_UNION	TCGA-XR-A8TF-01A-11D-A35Z-10	TCGA-XR-A8TF-10A-01D-A35Z-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1523L	0.177	113.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1523L (Missense)		LIHC_UNION	TCGA-DD-A1E9-01A-21D-A152-10	TCGA-DD-A1E9-11A-11D-A152-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R1224C	0.7143	21.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R1224C (Missense)		LIHC_UNION	TCGA-BC-A69H-01A-11D-A30V-10	TCGA-BC-A69H-10A-01D-A30V-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.A1078T	0.3432	169.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.A1078T (Missense)		LIHC_UNION	TCGA-ZP-A9D0-01A-11D-A36X-10	TCGA-ZP-A9D0-10A-01D-A370-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S679T	0.3571	56.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S679T (Missense)		LIHC_UNION	TCGA-FV-A3R2-01A-11D-A22F-10	TCGA-FV-A3R2-11A-11D-A22F-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.D346Y	0.4248	113.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.D346Y (Missense)		LIHC_UNION	TCGA-5R-AA1C-01A-11D-A40R-10	TCGA-5R-AA1C-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L238R	0.2443	131.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L238R (Missense)		LIHC_UNION	TCGA-2Y-A9GW-01A-11D-A382-10	TCGA-2Y-A9GW-10A-01D-A385-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Frameshift	p.Q186Rfs*21	0.5122	41.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.Q186Rfs*21 (Frameshift)		LIHC_UNION	TCGA-ED-A7PZ-01A-11D-A33Q-10	TCGA-ED-A7PZ-10A-01D-A33Q-10
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Insertion	p.P1536_P1543dup	0.3455	55.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P1536_P1543dup (Insertion)		LIHC_UNION	TCGA-DD-AAEB-01A-11D-A40R-10	TCGA-DD-AAEB-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.N1036S	0.4348	46.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.N1036S (Missense)		LIHC_UNION	TCGA-BC-A216-01A-11D-A152-10	TCGA-BC-A216-11A-11D-A152-10
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.Q32H	0.4901	202.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.Q32H (Missense)		LIHC_UNION	TCGA-CC-A8HT-01A-11D-A35Z-10	TCGA-CC-A8HT-10A-01D-A35Z-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Deletion	p.R137_Q140delinsK	0.3019	361.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R137_Q140delinsK (Deletion)		LIHC_UNION	TCGA-DD-A73C-01A-12D-A33K-10	TCGA-DD-A73C-10A-01D-A33K-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D279G	0.3046	614.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D279G (Missense)		LIHC_UNION	TCGA-DD-AAVP-01A-11D-A40R-10	TCGA-DD-AAVP-10A-01D-A40U-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.K290E	0.7489	223.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K290E (Missense)		LIHC_UNION	TCGA-FV-A4ZP-01A-12D-A25V-10	TCGA-FV-A4ZP-11A-12D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.K290E	0.7532	158.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K290E (Missense)		LIHC_UNION	TCGA-FV-A4ZP-01A-12D-A25V-10	TCGA-FV-A4ZP-11A-12D-A25V-10
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.P812S	0.1622	74.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.P812S (Missense)		LIHC_UNION	TCGA-DD-AAE0-01A-11D-A40R-10	TCGA-DD-AAE0-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R179I	0.1202	183.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R179I (Missense)		LIHC_UNION	TCGA-DD-AADO-01A-11D-A40R-10	TCGA-DD-AADO-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Frameshift	p.D757Rfs*18	0.2366	262.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D757Rfs*18 (Frameshift)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D1158G	0.3167	120.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D1158G (Missense)		LIHC_UNION	TCGA-DD-A4NF-01A-11D-A27I-10	TCGA-DD-A4NF-10A-01D-A27I-10
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.L1410I	0.1163	86.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.L1410I (Missense)		LIHC_UNION	TCGA-DD-AACD-01A-11D-A40R-10	TCGA-DD-AACD-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Deletion	p.I264_L266del	0.3333	33.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.I264_L266del (Deletion)		LIHC_UNION	TCGA-UB-AA0U-01A-11D-A382-10	TCGA-UB-AA0U-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.L31_I35del	0.2658	158.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L31_I35del (Deletion)		LIHC_UNION	TCGA-DD-A1EA-01A-11D-A12Z-10	TCGA-DD-A1EA-10A-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32N	0.4228	123.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32N (Missense)		LIHC_UNION	TCGA-DD-AAVY-01A-11D-A40R-10	TCGA-DD-AAVY-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32N	0.4431	167.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32N (Missense)		LIHC_UNION	TCGA-G3-AAV5-01A-11D-A36X-10	TCGA-G3-AAV5-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32N	0.3051	118.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32N (Missense)		LIHC_UNION	TCGA-UB-A7MD-01A-12D-A34Z-10	TCGA-UB-A7MD-10A-01D-A34Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32Y	0.3649	285.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32Y (Missense)		LIHC_UNION	TCGA-DD-A4NF-01A-11D-A27I-10	TCGA-DD-A4NF-10A-01D-A27I-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32Y	0.2925	147.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32Y (Missense)		LIHC_UNION	TCGA-G3-AAV3-01A-11D-A36X-10	TCGA-G3-AAV3-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.554	139.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-DD-A73D-01A-12D-A32G-10	TCGA-DD-A73D-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.2519	135.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-DD-AACB-01A-11D-A40R-10	TCGA-DD-AACB-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.4973	185.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-DD-AAW1-01A-11D-A40P-10	TCGA-DD-AAW1-10A-01D-A40P-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.9286	112.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-ED-A7PZ-01A-11D-A33Q-10	TCGA-ED-A7PZ-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.1368	95.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-EP-A2KC-01A-11D-A20W-10	TCGA-EP-A2KC-10A-01D-A20W-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.3192	213.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-G3-A5SL-01A-11D-A27I-10	TCGA-G3-A5SL-10A-01D-A27I-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.3252	246.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-G3-AAV1-01A-11D-A382-10	TCGA-G3-AAV1-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32V	0.2125	160.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32V (Missense)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32V	0.25	156.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32V (Missense)		LIHC_UNION	TCGA-CC-A7IL-01A-11D-A33Q-10	TCGA-CC-A7IL-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32V	0.3738	214.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32V (Missense)		LIHC_UNION	TCGA-DD-A73E-01A-12D-A32G-10	TCGA-DD-A73E-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32V	0.3432	169.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32V (Missense)		LIHC_UNION	TCGA-MI-A75H-01A-11D-A32G-10	TCGA-MI-A75H-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32V	0.4825	143.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32V (Missense)		LIHC_UNION	TCGA-RC-A6M4-01A-11D-A32G-10	TCGA-RC-A6M4-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32G	0.9245	106.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32G (Missense)		LIHC_UNION	TCGA-ED-A7PZ-01A-11D-A33Q-10	TCGA-ED-A7PZ-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.3188	207.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33P (Missense)		LIHC_UNION	TCGA-DD-A116-01A-11D-A12Z-10	TCGA-DD-A116-10A-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.3144	229.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33P (Missense)		LIHC_UNION	TCGA-DD-A39V-01A-11D-A20W-10	TCGA-DD-A39V-11A-11D-A20W-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.2969	128.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33P (Missense)		LIHC_UNION	TCGA-DD-AADE-01A-11D-A40R-10	TCGA-DD-AADE-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.2931	331.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33P (Missense)		LIHC_UNION	TCGA-G3-A3CK-01A-11D-A20W-10	TCGA-G3-A3CK-10A-01D-A20W-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33P	0.4459	148.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33P (Missense)		LIHC_UNION	TCGA-G3-A6UC-01A-21D-A33K-10	TCGA-G3-A6UC-10A-01D-A33K-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33A	0.4462	195.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33A (Missense)		LIHC_UNION	TCGA-EP-A12J-01A-11D-A12Z-10	TCGA-EP-A12J-10A-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33Y	0.295	139.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33Y (Missense)		LIHC_UNION	TCGA-CC-A5UD-01A-11D-A28X-10	TCGA-CC-A5UD-10A-01D-A28X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33Y	0.1429	147.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33Y (Missense)		LIHC_UNION	TCGA-DD-AACP-01A-11D-A40R-10	TCGA-DD-AACP-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33Y	0.3741	139.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33Y (Missense)		LIHC_UNION	TCGA-DD-AADD-01A-11D-A40R-10	TCGA-DD-AADD-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33C	0.1522	92.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33C (Missense)		LIHC_UNION	TCGA-DD-AAE3-01A-11D-A40R-10	TCGA-DD-AAE3-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33C	0.3407	182.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33C (Missense)		LIHC_UNION	TCGA-DD-AAEB-01A-11D-A40R-10	TCGA-DD-AAEB-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33C	0.4111	90.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33C (Missense)		LIHC_UNION	TCGA-DD-AAVX-01A-11D-A40R-10	TCGA-DD-AAVX-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33C	0.1186	118.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33C (Missense)		LIHC_UNION	TCGA-ED-A7XP-01A-11D-A34Z-10	TCGA-ED-A7XP-10A-01D-A34Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33C	0.2593	270.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33C (Missense)		LIHC_UNION	TCGA-FV-A4ZQ-01A-11D-A25V-10	TCGA-FV-A4ZQ-10A-01D-A25V-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33C	0.4823	141.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33C (Missense)		LIHC_UNION	TCGA-G3-AAV4-01A-11D-A382-10	TCGA-G3-AAV4-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33F	0.3333	60.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33F (Missense)		LIHC_UNION	TCGA-DD-AACA-01A-11D-A40R-10	TCGA-DD-AACA-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33F	0.3429	140.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33F (Missense)		LIHC_UNION	TCGA-XR-A8TF-01A-11D-A35Z-10	TCGA-XR-A8TF-10A-01D-A35Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.6993	153.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		LIHC_UNION	TCGA-ZS-A9CG-01A-11D-A36X-10	TCGA-ZS-A9CG-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34R	0.3277	119.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34R (Missense)		LIHC_UNION	TCGA-DD-AAC8-01A-11D-A40R-10	TCGA-DD-AAC8-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.3767	215.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		LIHC_UNION	TCGA-DD-A3A3-01A-11D-A22F-10	TCGA-DD-A3A3-11A-11D-A22F-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.1796	167.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		LIHC_UNION	TCGA-EP-A3RK-01A-11D-A22F-10	TCGA-EP-A3RK-10A-01D-A22F-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34V	0.359	117.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34V (Missense)		LIHC_UNION	TCGA-CC-A9FW-01A-11D-A36X-10	TCGA-CC-A9FW-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Insertion	p.I35_H36insNYQDDAELATRAI	0.6279	43.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.I35_H36insNYQDDAELATRAI (Insertion)		LIHC_UNION	TCGA-LG-A9QC-01A-11D-A36X-10	TCGA-LG-A9QC-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.I35S	0.3383	133.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.I35S (Missense)		LIHC_UNION	TCGA-DD-AACX-01A-11D-A40R-10	TCGA-DD-AACX-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.I35S	0.3478	92.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.I35S (Missense)		LIHC_UNION	TCGA-DD-AAVP-01A-11D-A40R-10	TCGA-DD-AAVP-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.I35S	0.4034	119.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.I35S (Missense)		LIHC_UNION	TCGA-ZP-A9D4-01A-11D-A36X-10	TCGA-ZP-A9D4-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.H36P	0.3048	374.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.H36P (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.H36P	0.3968	126.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.H36P (Missense)		LIHC_UNION	TCGA-DD-A1EL-01A-11D-A152-10	TCGA-DD-A1EL-10A-01D-A152-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.H36P	0.3015	272.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.H36P (Missense)		LIHC_UNION	TCGA-DD-A4NI-01A-11D-A27I-10	TCGA-DD-A4NI-10A-01D-A27I-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.H36P	0.2976	168.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.H36P (Missense)		LIHC_UNION	TCGA-DD-AACD-01A-11D-A40R-10	TCGA-DD-AACD-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.H36P	0.2892	332.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.H36P (Missense)		LIHC_UNION	TCGA-G3-A3CK-01A-11D-A20W-10	TCGA-G3-A3CK-10A-01D-A20W-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37A	0.1284	109.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37A (Missense)		LIHC_UNION	TCGA-DD-AAEK-01A-11D-A40R-10	TCGA-DD-AAEK-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37A	0.1538	156.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37A (Missense)		LIHC_UNION	TCGA-KR-A7K0-01A-12D-A33Q-10	TCGA-KR-A7K0-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37Y	0.4701	117.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37Y (Missense)		LIHC_UNION	TCGA-DD-AAD0-01A-11D-A40R-10	TCGA-DD-AAD0-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37C	0.3282	131.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37C (Missense)		LIHC_UNION	TCGA-DD-AADG-01A-11D-A40R-10	TCGA-DD-AADG-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37C	0.4286	112.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37C (Missense)		LIHC_UNION	TCGA-UB-A7MC-01A-11D-A33Q-10	TCGA-UB-A7MC-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.2148	135.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		LIHC_UNION	TCGA-5C-A9VG-01A-11D-A36X-10	TCGA-5C-A9VG-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.3786	243.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		LIHC_UNION	TCGA-BW-A5NQ-01A-11D-A27I-10	TCGA-BW-A5NQ-10A-01D-A27I-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.2214	131.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		LIHC_UNION	TCGA-2Y-A9HB-01A-11D-A38X-10	TCGA-2Y-A9HB-10A-01D-A38X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.3906	128.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		LIHC_UNION	TCGA-DD-AACJ-01A-11D-A40R-10	TCGA-DD-AACJ-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.5802	162.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		LIHC_UNION	TCGA-DD-AADU-01A-11D-A40R-10	TCGA-DD-AADU-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.5986	147.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		LIHC_UNION	TCGA-DD-AAE9-01A-11D-A40R-10	TCGA-DD-AAE9-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.5936	219.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		LIHC_UNION	TCGA-DD-AAW2-01A-11D-A40P-10	TCGA-DD-AAW2-10A-01D-A40P-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41I	0.4088	137.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41I (Missense)		LIHC_UNION	TCGA-2Y-A9HA-01A-11D-A38X-10	TCGA-2Y-A9HA-10A-01D-A38X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41I	0.4762	105.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41I (Missense)		LIHC_UNION	TCGA-EP-A26S-01A-11D-A16V-10	TCGA-EP-A26S-10A-01D-A16V-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Deletion	p.T42_K49del	0.6747	166.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T42_K49del (Deletion)		LIHC_UNION	TCGA-CC-A7IH-01A-11D-A33K-10	TCGA-CC-A7IH-10A-01D-A33K-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.8431	102.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-DD-AAW3-01A-11D-A40P-10	TCGA-DD-AAW3-10A-01D-A40P-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3611	144.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-2Y-A9H1-01A-11D-A382-10	TCGA-2Y-A9H1-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.5714	140.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-DD-AAEE-01A-11D-A40R-10	TCGA-DD-AAEE-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.395	119.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-DD-AAEH-01A-11D-A40R-10	TCGA-DD-AAEH-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.1455	110.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-DD-AAVQ-01A-11D-A40R-10	TCGA-DD-AAVQ-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.8349	109.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-DD-AAW3-01A-11D-A40P-10	TCGA-DD-AAW3-10A-01D-A40P-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.5824	182.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-G3-AAV2-01A-11D-A36X-10	TCGA-G3-AAV2-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3929	112.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-G3-AAV6-01A-21D-A36X-10	TCGA-G3-AAV6-10A-01D-A370-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.5	164.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-NI-A8LF-01A-11D-A35Z-10	TCGA-NI-A8LF-10A-01D-A35Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3013	156.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-O8-A75V-01A-11D-A32G-10	TCGA-O8-A75V-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.3791	153.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-RG-A7D4-01A-12D-A33Q-10	TCGA-RG-A7D4-10A-01D-A33Q-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45P	0.461	141.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45P (Missense)		LIHC_UNION	TCGA-WX-AA47-01A-11D-A38X-10	TCGA-WX-AA47-10A-01D-A38X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45Y	0.5444	169.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45Y (Missense)		LIHC_UNION	TCGA-5R-AA1C-01A-11D-A40R-10	TCGA-5R-AA1C-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45Y	0.4783	115.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45Y (Missense)		LIHC_UNION	TCGA-DD-A4NK-01A-11D-A28X-10	TCGA-DD-A4NK-10A-01D-A28X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45Y	0.4018	112.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45Y (Missense)		LIHC_UNION	TCGA-DD-AADE-01A-11D-A40R-10	TCGA-DD-AADE-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.4915	118.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		LIHC_UNION	TCGA-3K-AAZ8-01A-12D-A38X-10	TCGA-3K-AAZ8-10A-01D-A38X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.375	176.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.3197	147.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		LIHC_UNION	TCGA-LG-A9QD-01A-11D-A382-10	TCGA-LG-A9QD-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.3091	110.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		LIHC_UNION	TCGA-ZP-A9CV-01A-11D-A382-10	TCGA-ZP-A9CV-10B-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.E54D	0.57	207.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.E54D (Missense)		LIHC_UNION	TCGA-DD-AAW2-01A-11D-A40P-10	TCGA-DD-AAW2-10A-01D-A40P-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R185G	0.3088	136.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R185G (Missense)		LIHC_UNION	TCGA-EP-A2KA-01A-11D-A183-10	TCGA-EP-A2KA-10A-01D-A183-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.Y333F	0.3684	38.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.Y333F (Missense)		LIHC_UNION	TCGA-G3-A5SJ-01A-11D-A27I-10	TCGA-G3-A5SJ-10A-01D-A27I-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335T	0.213	108.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335T (Missense)		LIHC_UNION	TCGA-K7-A6G5-01A-11D-A30V-10	TCGA-K7-A6G5-10A-01D-A30V-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.0725	138.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335I (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.503	167.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335I (Missense)		LIHC_UNION	TCGA-DD-A1EJ-01A-11D-A152-10	TCGA-DD-A1EJ-10A-01D-A152-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.4384	73.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335I (Missense)		LIHC_UNION	TCGA-DD-A3A4-01A-11D-A22F-10	TCGA-DD-A3A4-11A-11D-A22F-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.2581	62.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335I (Missense)		LIHC_UNION	TCGA-DD-A4NL-01A-11D-A28X-10	TCGA-DD-A4NL-11A-11D-A28X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.3939	99.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335I (Missense)		LIHC_UNION	TCGA-DD-AACK-01A-11D-A40R-10	TCGA-DD-AACK-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.K335I	0.4	65.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.K335I (Missense)		LIHC_UNION	TCGA-MI-A75C-01A-11D-A32G-10	TCGA-MI-A75C-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L368H	0.4891	184.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L368H (Missense)		LIHC_UNION	TCGA-BC-A5W4-01A-11D-A28X-10	TCGA-BC-A5W4-10A-01D-A28X-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.W383C	0.2088	249.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.W383C (Missense)		LIHC_UNION	TCGA-CC-5262-01A-01D-A12Z-10	TCGA-CC-5262-10B-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N387Y	0.3818	165.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N387Y (Missense)		LIHC_UNION	TCGA-BC-A69H-01A-11D-A30V-10	TCGA-BC-A69H-10A-01D-A30V-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N387I	0.3014	146.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N387I (Missense)		LIHC_UNION	TCGA-DD-A73A-01A-12D-A32G-10	TCGA-DD-A73A-10A-01D-A32G-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N387K	0.1259	143.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N387K (Missense)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N387K	0.2083	96.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N387K (Missense)		LIHC_UNION	TCGA-EP-A3JL-01A-11D-A20W-10	TCGA-EP-A3JL-10A-01D-A20W-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.N387K	0.3543	127.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.N387K (Missense)		LIHC_UNION	TCGA-FV-A2QQ-01A-11D-A22F-10	TCGA-FV-A2QQ-10B-01D-A22F-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L405F	0.0545	110.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L405F (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.L405F	0.3115	61.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.L405F (Missense)		LIHC_UNION	TCGA-G3-A25Z-01A-11D-A16V-10	TCGA-G3-A25Z-10A-01D-A16V-10
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Frameshift	p.C419Sfs*6	0.0676	74.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.C419Sfs*6 (Frameshift)		LIHC_UNION	TCGA-DD-AAD1-01A-11D-A40R-10	TCGA-DD-AAD1-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E62D	0.641	39.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E62D (Missense)		LIHC_UNION	TCGA-LG-A9QD-01A-11D-A382-10	TCGA-LG-A9QD-10A-01D-A385-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Deletion	p.L320_Y323del	0.2222	108.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.L320_Y323del (Deletion)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Deletion	p.K536_L539del	0.8421	38.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.K536_L539del (Deletion)		LIHC_UNION	TCGA-ES-A2HS-01A-11D-A183-10	TCGA-ES-A2HS-11A-11D-A183-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I2501F	0.0826	121.0	0.0	0.0																									MTOR p.I2501F (Missense)		LIHC_UNION	TCGA-DD-A11A-01A-11D-A12Z-10	TCGA-DD-A11A-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.S2215Y	0.1333	105.0	0.0	0.0																									MTOR p.S2215Y (Missense)		LIHC_UNION	TCGA-DD-AADK-01A-11D-A40R-10	TCGA-DD-AADK-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.M1595V	0.6667	39.0	0.0	0.0																									MTOR p.M1595V (Missense)		LIHC_UNION	TCGA-DD-A1EF-01A-11D-A12Z-10	TCGA-DD-A1EF-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.D670H	0.3203	153.0	0.0	0.0																									MTOR p.D670H (Missense)		LIHC_UNION	TCGA-CC-A5UC-01A-11D-A28X-10	TCGA-CC-A5UC-10A-01D-A28X-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.I501N	0.3117	77.0	0.0	0.0																									MTOR p.I501N (Missense)		LIHC_UNION	TCGA-DD-AACQ-01A-11D-A40R-10	TCGA-DD-AACQ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	MTOR	Splice Site	p.X168_splice	0.6538	26.0	0.0	0.0																									MTOR p.X168_splice (Splice Site)		LIHC_UNION	TCGA-EP-A2KC-01A-11D-A20W-10	TCGA-EP-A2KC-10A-01D-A20W-10
Biologically Relevant				Somatic Variant	MTOR	Missense	p.M135V	0.6884	215.0	0.0	0.0																									MTOR p.M135V (Missense)		LIHC_UNION	TCGA-G3-A5SJ-01A-11D-A27I-10	TCGA-G3-A5SJ-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.A72T	0.3279	122.0	0.0	0.0																									CDKN2C p.A72T (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.F385L	0.3429	70.0	0.0	0.0																									NTRK1 p.F385L (Missense)		LIHC_UNION	TCGA-G3-A7M9-01A-23D-A34Z-10	TCGA-G3-A7M9-10A-01D-A34Z-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.V658A	0.3429	35.0	0.0	0.0																									NTRK1 p.V658A (Missense)		LIHC_UNION	TCGA-DD-AADE-01A-11D-A40R-10	TCGA-DD-AADE-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.P695S	0.0663	181.0	0.0	0.0																									NTRK1 p.P695S (Missense)		LIHC_UNION	TCGA-UB-A7MC-01A-11D-A33Q-10	TCGA-UB-A7MC-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.R771C	0.123	187.0	0.0	0.0																									NTRK1 p.R771C (Missense)		LIHC_UNION	TCGA-DD-AADO-01A-11D-A40R-10	TCGA-DD-AADO-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.Y791N	0.1373	153.0	0.0	0.0																									NTRK1 p.Y791N (Missense)		LIHC_UNION	TCGA-BD-A3ER-01A-11D-A20W-10	TCGA-BD-A3ER-11A-11D-A20W-10
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.L453M	0.8194	72.0	0.0	0.0																									SLC45A3 p.L453M (Missense)		LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.L453M	0.8235	68.0	0.0	0.0																									SLC45A3 p.L453M (Missense)		LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.D408G	0.1973	147.0	0.0	0.0																									FGFR2 p.D408G (Missense)		LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.A344S	0.2683	82.0	0.0	0.0																									FGFR2 p.A344S (Missense)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	FGFR2	Deletion	p.H167_N173del	0.2667	60.0	0.0	0.0																									FGFR2 p.H167_N173del (Deletion)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P99S	0.5658	76.0	0.0	0.0																									FGFR2 p.P99S (Missense)		LIHC_UNION	TCGA-FV-A3I0-01A-11D-A22F-10	TCGA-FV-A3I0-11A-11D-A22F-10
Biologically Relevant				Somatic Variant	CCND1	Missense	p.A205V	0.1282	39.0	0.0	0.0																									CCND1 p.A205V (Missense)		LIHC_UNION	TCGA-DD-AADO-01A-11D-A40R-10	TCGA-DD-AADO-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	PAK1	Missense	p.T167S	0.2083	48.0	0.0	0.0																									PAK1 p.T167S (Missense)		LIHC_UNION	TCGA-DD-AACT-01A-11D-A40R-10	TCGA-DD-AACT-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	PAK1	Missense	p.E166V	0.2222	45.0	0.0	0.0																									PAK1 p.E166V (Missense)		LIHC_UNION	TCGA-DD-AACT-01A-11D-A40R-10	TCGA-DD-AACT-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	FLI1	Missense	p.A25G	0.25	64.0	0.0	0.0																									FLI1 p.A25G (Missense)		LIHC_UNION	TCGA-DD-AAEG-01A-11D-A38X-10	TCGA-DD-AAEG-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S292T	0.2963	81.0	0.0	0.0																									FLI1 p.S292T (Missense)		LIHC_UNION	TCGA-DD-AACK-01A-11D-A40R-10	TCGA-DD-AACK-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	FLI1	Missense	p.S298N	0.2927	41.0	0.0	0.0																									FLI1 p.S298N (Missense)		LIHC_UNION	TCGA-BW-A5NP-01A-11D-A27I-10	TCGA-BW-A5NP-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	MDM2	Missense	p.E316D	0.4839	31.0	0.0	0.0																									MDM2 p.E316D (Missense)		LIHC_UNION	TCGA-RC-A6M4-01A-11D-A32G-10	TCGA-RC-A6M4-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R7Gfs*9	0.6687	492.0	0.0	0.0																									RB1 p.R7Gfs*9 (Frameshift)		LIHC_UNION	TCGA-DD-AADW-01A-11D-A38X-10	TCGA-DD-AADW-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.I66K	0.7451	51.0	0.0	0.0																									RB1 p.I66K (Missense)		LIHC_UNION	TCGA-CC-A8HU-01A-11D-A35Z-10	TCGA-CC-A8HU-10A-01D-A35Z-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.P67A	0.7843	51.0	0.0	0.0																									RB1 p.P67A (Missense)		LIHC_UNION	TCGA-CC-A8HU-01A-11D-A35Z-10	TCGA-CC-A8HU-10A-01D-A35Z-10
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.W78*	0.7411	224.0	0.0	0.0																									RB1 p.W78* (Nonsense)		LIHC_UNION	TCGA-DD-A113-01A-11D-A12Z-10	TCGA-DD-A113-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.F162Lfs*9	0.8125	32.0	0.0	0.0																									RB1 p.F162Lfs*9 (Frameshift)		LIHC_UNION	TCGA-DD-A4NE-01A-11D-A27I-10	TCGA-DD-A4NE-11A-11D-A27I-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.F162Lfs*9	0.75	24.0	0.0	0.0																									RB1 p.F162Lfs*9 (Frameshift)		LIHC_UNION	TCGA-DD-A4NE-01A-11D-A27I-10	TCGA-DD-A4NE-11A-11D-A27I-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X180_splice	0.5758	33.0	0.0	0.0																									RB1 p.X180_splice (Splice Site)		LIHC_UNION	TCGA-WX-AA44-01A-11D-A38X-10	TCGA-WX-AA44-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X203_splice	0.4211	38.0	0.0	0.0																									RB1 p.X203_splice (Splice Site)		LIHC_UNION	TCGA-G3-AAV7-01A-11D-A382-10	TCGA-G3-AAV7-10A-01D-A385-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R254Gfs*10	0.1616	198.0	0.0	0.0																									RB1 p.R254Gfs*10 (Frameshift)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.N290Kfs*20	0.4948	192.0	0.0	0.0																									RB1 p.N290Kfs*20 (Frameshift)		LIHC_UNION	TCGA-BC-A10W-01A-11D-A12Z-10	TCGA-BC-A10W-11A-11D-A12Z-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.N316Y	0.5	12.0	0.0	0.0																									RB1 p.N316Y (Missense)		LIHC_UNION	TCGA-DD-A4NJ-01A-11D-A27I-10	TCGA-DD-A4NJ-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.N399Kfs*7	0.1904	520.0	0.0	0.0																									RB1 p.N399Kfs*7 (Frameshift)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.N399Kfs*7	0.9094	298.0	0.0	0.0																									RB1 p.N399Kfs*7 (Frameshift)		LIHC_UNION	TCGA-G3-A25U-01A-11D-A16V-10	TCGA-G3-A25U-10A-01D-A16V-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.N399Kfs*7	0.8494	239.0	0.0	0.0																									RB1 p.N399Kfs*7 (Frameshift)		LIHC_UNION	TCGA-G3-A25U-01A-11D-A16V-10	TCGA-G3-A25U-10A-01D-A16V-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X406_splice	0.875	48.0	0.0	0.0																									RB1 p.X406_splice (Splice Site)		LIHC_UNION	TCGA-ED-A66Y-01A-11D-A30V-10	TCGA-ED-A66Y-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X406_splice	0.871	62.0	0.0	0.0																									RB1 p.X406_splice (Splice Site)		LIHC_UNION	TCGA-ED-A66Y-01A-11D-A30V-10	TCGA-ED-A66Y-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X445_splice	0.3333	129.0	0.0	0.0																									RB1 p.X445_splice (Splice Site)		LIHC_UNION	TCGA-G3-A25Y-01A-11D-A16V-10	TCGA-G3-A25Y-10A-01D-A16V-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.V450Sfs*13	0.7619	21.0	0.0	0.0																									RB1 p.V450Sfs*13 (Frameshift)		LIHC_UNION	TCGA-G3-A5SI-01A-31D-A27I-10	TCGA-G3-A5SI-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R451Afs*6	0.9119	159.0	0.0	0.0																									RB1 p.R451Afs*6 (Frameshift)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R451Afs*6	0.9208	202.0	0.0	0.0																									RB1 p.R451Afs*6 (Frameshift)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X463_splice	0.6857	70.0	0.0	0.0																									RB1 p.X463_splice (Splice Site)		LIHC_UNION	TCGA-RC-A7S9-01A-11D-A33Q-10	TCGA-RC-A7S9-10A-02D-A33Q-10
Biologically Relevant				Somatic Variant	RB1	Deletion	p.H483_S485del	0.5686	51.0	0.0	0.0																									RB1 p.H483_S485del (Deletion)		LIHC_UNION	TCGA-CC-A7IF-01A-11D-A33K-10	TCGA-CC-A7IF-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X500_splice	0.5306	98.0	0.0	0.0																									RB1 p.X500_splice (Splice Site)		LIHC_UNION	TCGA-G3-A3CH-01A-11D-A22F-10	TCGA-G3-A3CH-11A-11D-A22F-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.E580D	0.3333	30.0	0.0	0.0																									RB1 p.E580D (Missense)		LIHC_UNION	TCGA-ED-A7PZ-01A-11D-A33Q-10	TCGA-ED-A7PZ-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	RB1	Missense	p.T638S	0.4237	262.0	0.0	0.0																									RB1 p.T638S (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.V654Sfs*14	0.1839	87.0	0.0	0.0																									RB1 p.V654Sfs*14 (Frameshift)		LIHC_UNION	TCGA-DD-A114-01A-11D-A12Z-10	TCGA-DD-A114-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.I723Sfs*3	0.6278	352.0	0.0	0.0																									RB1 p.I723Sfs*3 (Frameshift)		LIHC_UNION	TCGA-5C-AAPD-01A-21D-A38X-10	TCGA-5C-AAPD-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	RB1	Deletion	p.V759_L769del	0.475	80.0	0.0	0.0																									RB1 p.V759_L769del (Deletion)		LIHC_UNION	TCGA-CC-A7IG-01A-11D-A33K-10	TCGA-CC-A7IG-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	POLE2	Missense	p.Q139L	0.4205	88.0	0.0	0.0																									POLE2 p.Q139L (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.S701T	0.4295	156.0	0.0	0.0																									NTRK3 p.S701T (Missense)		LIHC_UNION	TCGA-CC-A7IH-01A-11D-A33K-10	TCGA-CC-A7IH-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H622N	0.3553	76.0	0.0	0.0																									NTRK3 p.H622N (Missense)		LIHC_UNION	TCGA-DD-AAD0-01A-11D-A40R-10	TCGA-DD-AAD0-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D527G	0.4062	64.0	0.0	0.0																									NTRK3 p.D527G (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.F395Y	0.2697	152.0	0.0	0.0																									NTRK3 p.F395Y (Missense)		LIHC_UNION	TCGA-DD-AAEA-01A-11D-A40R-10	TCGA-DD-AAEA-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.P331S	0.1205	83.0	0.0	0.0																									NTRK3 p.P331S (Missense)		LIHC_UNION	TCGA-DD-AADO-01A-11D-A40R-10	TCGA-DD-AADO-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E318D	0.2394	71.0	0.0	0.0																									NTRK3 p.E318D (Missense)		LIHC_UNION	TCGA-G3-AAV3-01A-11D-A36X-10	TCGA-G3-AAV3-10A-01D-A370-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.G233S	0.3871	93.0	0.0	0.0																									NTRK3 p.G233S (Missense)		LIHC_UNION	TCGA-2Y-A9GY-01A-11D-A382-10	TCGA-2Y-A9GY-10A-01D-A385-10
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.Q145R	0.5155	161.0	0.0	0.0																									NTRK3 p.Q145R (Missense)		LIHC_UNION	TCGA-2Y-A9HB-01A-11D-A38X-10	TCGA-2Y-A9HB-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.K480Nfs*18	0.5026	193.0	0.0	0.0																									NF1 p.K480Nfs*18 (Frameshift)		LIHC_UNION	TCGA-DD-A3A3-01A-11D-A22F-10	TCGA-DD-A3A3-11A-11D-A22F-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.M748R	0.4419	86.0	0.0	0.0																									NF1 p.M748R (Missense)		LIHC_UNION	TCGA-DD-A4NJ-01A-11D-A27I-10	TCGA-DD-A4NJ-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.K796N	0.125	136.0	0.0	0.0																									NF1 p.K796N (Missense)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.Q1189H	0.4583	144.0	0.0	0.0																									NF1 p.Q1189H (Missense)		LIHC_UNION	TCGA-DD-AAD8-01A-11D-A40R-10	TCGA-DD-AAD8-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X1370_splice	0.3	90.0	0.0	0.0																									NF1 p.X1370_splice (Splice Site)		LIHC_UNION	TCGA-FV-A2QR-01A-11D-A20W-10	TCGA-FV-A2QR-11A-11D-A20W-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.F1467L	0.0435	115.0	0.0	0.0																									NF1 p.F1467L (Missense)		LIHC_UNION	TCGA-DD-AAE9-01A-11D-A40R-10	TCGA-DD-AAE9-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.F1479Sfs*4	0.3	40.0	0.0	0.0																									NF1 p.F1479Sfs*4 (Frameshift)		LIHC_UNION	TCGA-ED-A97K-01A-21D-A382-10	TCGA-ED-A97K-10A-01D-A385-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.A1544T	0.2862	290.0	0.0	0.0																									NF1 p.A1544T (Missense)		LIHC_UNION	TCGA-ZP-A9CZ-01A-11D-A382-10	TCGA-ZP-A9CZ-10A-01D-A385-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1591N	0.3882	85.0	0.0	0.0																									NF1 p.S1591N (Missense)		LIHC_UNION	TCGA-RC-A7S9-01A-11D-A33Q-10	TCGA-RC-A7S9-10A-02D-A33Q-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1599Y	0.0635	299.0	0.0	0.0																									NF1 p.S1599Y (Missense)		LIHC_UNION	TCGA-DD-A4NS-01A-11D-A30V-10	TCGA-DD-A4NS-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	NF1	Missense	p.I1803V	0.5192	104.0	0.0	0.0																									NF1 p.I1803V (Missense)		LIHC_UNION	TCGA-DD-AADV-01A-11D-A38X-10	TCGA-DD-AADV-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	NF1	Deletion	p.T1923_L1927delinsM	0.2553	94.0	0.0	0.0																									NF1 p.T1923_L1927delinsM (Deletion)		LIHC_UNION	TCGA-DD-AACM-01A-11D-A40R-10	TCGA-DD-AACM-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.I1931Lfs*12	0.0693	101.0	0.0	0.0																									NF1 p.I1931Lfs*12 (Frameshift)		LIHC_UNION	TCGA-DD-A4NS-01A-11D-A30V-10	TCGA-DD-A4NS-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.H1418D	0.197	66.0	0.0	0.0																									COL1A1 p.H1418D (Missense)		LIHC_UNION	TCGA-DD-AACQ-01A-11D-A40R-10	TCGA-DD-AACQ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.T1367I	0.1951	82.0	0.0	0.0																									COL1A1 p.T1367I (Missense)		LIHC_UNION	TCGA-2V-A95S-01A-11D-A36X-10	TCGA-2V-A95S-10D-01D-A370-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.L1229H	0.4878	82.0	0.0	0.0																									COL1A1 p.L1229H (Missense)		LIHC_UNION	TCGA-G3-A5SL-01A-11D-A27I-10	TCGA-G3-A5SL-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R994S	0.3396	106.0	0.0	0.0																									COL1A1 p.R994S (Missense)		LIHC_UNION	TCGA-DD-AACY-01A-11D-A40R-10	TCGA-DD-AACY-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	COL1A1	Frameshift	p.G145Dfs*120	0.1991	221.0	0.0	0.0																									COL1A1 p.G145Dfs*120 (Frameshift)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D132V	0.1925	161.0	0.0	0.0																									COL1A1 p.D132V (Missense)		LIHC_UNION	TCGA-DD-AACT-01A-11D-A40R-10	TCGA-DD-AACT-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S592G	0.1538	65.0	0.0	0.0																									KEAP1 p.S592G (Missense)		LIHC_UNION	TCGA-2Y-A9H3-01A-11D-A382-10	TCGA-2Y-A9H3-10A-01D-A385-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.Y525C	0.0608	148.0	0.0	0.0																									KEAP1 p.Y525C (Missense)		LIHC_UNION	TCGA-ED-A4XI-01A-11D-A25V-10	TCGA-ED-A4XI-10A-01D-A25V-10
Biologically Relevant				Somatic Variant	KEAP1	Frameshift	p.I519Mfs*12	0.6129	62.0	0.0	0.0																									KEAP1 p.I519Mfs*12 (Frameshift)		LIHC_UNION	TCGA-DD-AACO-01A-11D-A40R-10	TCGA-DD-AACO-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.G429D	0.1081	37.0	0.0	0.0																									KEAP1 p.G429D (Missense)		LIHC_UNION	TCGA-DD-AAEG-01A-11D-A38X-10	TCGA-DD-AAEG-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.G379V	0.1226	106.0	0.0	0.0																									KEAP1 p.G379V (Missense)		LIHC_UNION	TCGA-K7-A5RG-01A-11D-A28X-10	TCGA-K7-A5RG-10A-01D-A28X-10
Biologically Relevant				Somatic Variant	KEAP1	Frameshift	p.L355Sfs*37	0.4474	76.0	0.0	0.0																									KEAP1 p.L355Sfs*37 (Frameshift)		LIHC_UNION	TCGA-2Y-A9GS-01A-12D-A382-10	TCGA-2Y-A9GS-10A-01D-A385-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.H311L	0.5263	95.0	0.0	0.0																									KEAP1 p.H311L (Missense)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.P278L	0.4571	35.0	0.0	0.0																									KEAP1 p.P278L (Missense)		LIHC_UNION	TCGA-CC-A7IK-01A-12D-A33Q-10	TCGA-CC-A7IK-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.V271L	0.7561	41.0	0.0	0.0																									KEAP1 p.V271L (Missense)		LIHC_UNION	TCGA-DD-A1EL-01A-11D-A152-10	TCGA-DD-A1EL-10A-01D-A152-10
Biologically Relevant				Somatic Variant	KEAP1	Frameshift	p.D256Vfs*95	0.2258	93.0	0.0	0.0																									KEAP1 p.D256Vfs*95 (Frameshift)		LIHC_UNION	TCGA-G3-A3CK-01A-11D-A20W-10	TCGA-G3-A3CK-10A-01D-A20W-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.G186S	0.75	40.0	0.0	0.0																									KEAP1 p.G186S (Missense)		LIHC_UNION	TCGA-BC-A8YO-01A-11D-A36X-10	TCGA-BC-A8YO-10A-01D-A370-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.V168G	0.3394	109.0	0.0	0.0																									KEAP1 p.V168G (Missense)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.N157S	0.1519	79.0	0.0	0.0																									KEAP1 p.N157S (Missense)		LIHC_UNION	TCGA-DD-AAE7-01A-11D-A40R-10	TCGA-DD-AAE7-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.V152G	0.4062	64.0	0.0	0.0																									KEAP1 p.V152G (Missense)		LIHC_UNION	TCGA-2Y-A9GY-01A-11D-A382-10	TCGA-2Y-A9GY-10A-01D-A385-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.I137T	0.0943	53.0	0.0	0.0																									KEAP1 p.I137T (Missense)		LIHC_UNION	TCGA-DD-A4NR-01A-11D-A30V-10	TCGA-DD-A4NR-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	KEAP1	Frameshift	p.G127Vfs*30	0.7188	64.0	0.0	0.0																									KEAP1 p.G127Vfs*30 (Frameshift)		LIHC_UNION	TCGA-DD-AACB-01A-11D-A40R-10	TCGA-DD-AACB-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.L115Q	0.35	80.0	0.0	0.0																									KEAP1 p.L115Q (Missense)		LIHC_UNION	TCGA-G3-AAV5-01A-11D-A36X-10	TCGA-G3-AAV5-10A-01D-A370-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S104R	0.3537	147.0	0.0	0.0																									KEAP1 p.S104R (Missense)		LIHC_UNION	TCGA-G3-A3CK-01A-11D-A20W-10	TCGA-G3-A3CK-10A-01D-A20W-10
Biologically Relevant				Somatic Variant	KEAP1	Nonsense	p.K97*	0.7619	42.0	0.0	0.0																									KEAP1 p.K97* (Nonsense)		LIHC_UNION	TCGA-DD-AACQ-01A-11D-A40R-10	TCGA-DD-AACQ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Nonsense	p.K97*	0.7391	46.0	0.0	0.0																									KEAP1 p.K97* (Nonsense)		LIHC_UNION	TCGA-DD-AACQ-01A-11D-A40R-10	TCGA-DD-AACQ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.P89L	0.7714	35.0	0.0	0.0																									KEAP1 p.P89L (Missense)		LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.P89L	0.7895	38.0	0.0	0.0																									KEAP1 p.P89L (Missense)		LIHC_UNION	TCGA-RC-A6M6-01A-11D-A32G-10	TCGA-RC-A6M6-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	BRD4	Nonsense	p.E1332*	0.4882	127.0	0.0	0.0																									BRD4 p.E1332* (Nonsense)		LIHC_UNION	TCGA-DD-A4NN-01A-11D-A28X-10	TCGA-DD-A4NN-10A-01D-A28X-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L1096P	0.8095	42.0	0.0	0.0																									BRD4 p.L1096P (Missense)		LIHC_UNION	TCGA-DD-AACP-01A-11D-A40R-10	TCGA-DD-AACP-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.L1096P	0.8	40.0	0.0	0.0																									BRD4 p.L1096P (Missense)		LIHC_UNION	TCGA-DD-AACP-01A-11D-A40R-10	TCGA-DD-AACP-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.H1081Y	0.427	89.0	0.0	0.0																									BRD4 p.H1081Y (Missense)		LIHC_UNION	TCGA-DD-A11B-01A-11D-A12Z-10	TCGA-DD-A11B-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	BRD4	Frameshift	p.P833Lfs*58	0.2857	14.0	0.0	0.0																									BRD4 p.P833Lfs*58 (Frameshift)		LIHC_UNION	TCGA-DD-A73G-01A-22D-A32G-10	TCGA-DD-A73G-10A-01D-A32G-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P810S	0.3611	72.0	0.0	0.0																									BRD4 p.P810S (Missense)		LIHC_UNION	TCGA-DD-AADS-01A-11D-A40R-10	TCGA-DD-AADS-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.M457L	0.3333	24.0	0.0	0.0																									BRD4 p.M457L (Missense)		LIHC_UNION	TCGA-DD-A3A7-01A-11D-A22F-10	TCGA-DD-A3A7-11A-11D-A22F-10
Biologically Relevant				Somatic Variant	BRD4	Missense	p.Q201P	0.1371	299.0	0.0	0.0																									BRD4 p.Q201P (Missense)		LIHC_UNION	TCGA-DD-A1EF-01A-11D-A12Z-10	TCGA-DD-A1EF-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.D606Y	0.3662	71.0	0.0	0.0																									IL12RB1 p.D606Y (Missense)		LIHC_UNION	TCGA-DD-AAEB-01A-11D-A40R-10	TCGA-DD-AAEB-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.I590T	0.4556	248.0	0.0	0.0																									IL12RB1 p.I590T (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.S290P	0.1053	171.0	0.0	0.0																									IL12RB1 p.S290P (Missense)		LIHC_UNION	TCGA-DD-A3A9-01A-11D-A25V-10	TCGA-DD-A3A9-11A-11D-A25V-10
Biologically Relevant				Somatic Variant	IL12RB1	Nonsense	p.Q171*	0.3396	53.0	0.0	0.0																									IL12RB1 p.Q171* (Nonsense)		LIHC_UNION	TCGA-DD-A11C-01A-11D-A12Z-10	TCGA-DD-A11C-11A-11D-A12Z-10
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.G192A	0.2469	81.0	0.0	0.0																									CCNE1 p.G192A (Missense)		LIHC_UNION	TCGA-BW-A5NQ-01A-11D-A27I-10	TCGA-BW-A5NQ-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	EML4	Nonsense	p.R142*	0.16	50.0	0.0	0.0																									EML4 p.R142* (Nonsense)		LIHC_UNION	TCGA-DD-A4NA-01A-11D-A25V-10	TCGA-DD-A4NA-11A-11D-A25V-10
Biologically Relevant				Somatic Variant	EML4	Missense	p.R614W	0.4307	137.0	0.0	0.0																									EML4 p.R614W (Missense)		LIHC_UNION	TCGA-G3-A7M5-01A-11D-A33Q-10	TCGA-G3-A7M5-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	EML4	Missense	p.I792F	0.1795	78.0	0.0	0.0																									EML4 p.I792F (Missense)		LIHC_UNION	TCGA-DD-AADF-01A-11D-A40R-10	TCGA-DD-AADF-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	EML4	Missense	p.E911K	0.4608	102.0	0.0	0.0																									EML4 p.E911K (Missense)		LIHC_UNION	TCGA-DD-AADJ-01A-11D-A40R-10	TCGA-DD-AADJ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	TPX2	Missense	p.S252I	0.0909	66.0	0.0	0.0																									TPX2 p.S252I (Missense)		LIHC_UNION	TCGA-DD-A1ED-01A-11D-A152-10	TCGA-DD-A1ED-10A-01D-A152-10
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R263L	0.4414	145.0	0.0	0.0																									TPX2 p.R263L (Missense)		LIHC_UNION	TCGA-G3-A5SI-01A-31D-A27I-10	TCGA-G3-A5SI-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K448M	0.3543	127.0	0.0	0.0																									TPX2 p.K448M (Missense)		LIHC_UNION	TCGA-DD-AADA-01A-11D-A40R-10	TCGA-DD-AADA-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P522L	0.4071	226.0	0.0	0.0																									TPX2 p.P522L (Missense)		LIHC_UNION	TCGA-G3-AAV4-01A-11D-A382-10	TCGA-G3-AAV4-10A-01D-A385-10
Biologically Relevant				Somatic Variant	AURKA	Missense	p.R180K	0.0761	92.0	0.0	0.0																									AURKA p.R180K (Missense)		LIHC_UNION	TCGA-DD-A4NS-01A-11D-A30V-10	TCGA-DD-A4NS-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	AURKA	Missense	p.S83N	0.3799	179.0	0.0	0.0																									AURKA p.S83N (Missense)		LIHC_UNION	TCGA-ED-A7XP-01A-11D-A34Z-10	TCGA-ED-A7XP-10A-01D-A34Z-10
Biologically Relevant				Somatic Variant	ERG	Missense	p.M425I	0.1538	78.0	0.0	0.0																									ERG p.M425I (Missense)		LIHC_UNION	TCGA-KR-A7K8-01A-11D-A33K-10	TCGA-KR-A7K8-10A-01D-A33K-10
Biologically Relevant				Somatic Variant	ERG	Missense	p.L16V	0.1889	270.0	0.0	0.0																									ERG p.L16V (Missense)		LIHC_UNION	TCGA-BW-A5NQ-01A-11D-A27I-10	TCGA-BW-A5NQ-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.A294V	0.3273	110.0	0.0	0.0																									TMPRSS2 p.A294V (Missense)		LIHC_UNION	TCGA-DD-AACT-01A-11D-A40R-10	TCGA-DD-AACT-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.T4R	0.2439	41.0	0.0	0.0																									EWSR1 p.T4R (Missense)		LIHC_UNION	TCGA-K7-A6G5-01A-11D-A30V-10	TCGA-K7-A6G5-10A-01D-A30V-10
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R565I	0.1852	108.0	0.0	0.0																									EWSR1 p.R565I (Missense)		LIHC_UNION	TCGA-ED-A7XO-01A-11D-A34Z-10	TCGA-ED-A7XO-10A-01D-A34Z-10
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E140G	0.3333	30.0	0.0	0.0																									LIMK2 p.E140G (Missense)		LIHC_UNION	TCGA-DD-A3A8-01A-11D-A22F-10	TCGA-DD-A3A8-11A-11D-A22F-10
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.D524H	0.2692	52.0	0.0	0.0																									LIMK2 p.D524H (Missense)		LIHC_UNION	TCGA-G3-A7M6-01A-11D-A33Q-10	TCGA-G3-A7M6-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	PDGFB	Nonsense	p.Q205*	0.1549	71.0	0.0	0.0																									PDGFB p.Q205* (Nonsense)		LIHC_UNION	TCGA-G3-A25Y-01A-11D-A16V-10	TCGA-G3-A25Y-10A-01D-A16V-10
Biologically Relevant				Somatic Variant	RAF1	Missense	p.P261R	0.4474	114.0	0.0	0.0																									RAF1 p.P261R (Missense)		LIHC_UNION	TCGA-BC-A10Q-01A-11D-A12Z-10	TCGA-BC-A10Q-11A-11D-A12Z-10
Biologically Relevant				Somatic Variant	MLH1	Missense	p.A202G	0.3168	161.0	0.0	0.0																									MLH1 p.A202G (Missense)		LIHC_UNION	TCGA-BC-A10W-01A-11D-A12Z-10	TCGA-BC-A10W-11A-11D-A12Z-10
Biologically Relevant				Somatic Variant	TACC3	Frameshift	p.M396Cfs*65	0.2857	147.0	0.0	0.0																									TACC3 p.M396Cfs*65 (Frameshift)		LIHC_UNION	TCGA-WQ-A9G7-01A-11D-A36X-10	TCGA-WQ-A9G7-10A-01D-A370-10
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.E154Q	0.2203	59.0	0.0	0.0																									FIP1L1 p.E154Q (Missense)		LIHC_UNION	TCGA-BW-A5NO-01A-11D-A27I-10	TCGA-BW-A5NO-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.D1018E	0.3878	49.0	0.0	0.0																									PDGFRB p.D1018E (Missense)		LIHC_UNION	TCGA-DD-A1EE-01A-11D-A12Z-10	TCGA-DD-A1EE-10A-01D-A12Z-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H2310P	0.4505	111.0	0.0	0.0																									ROS1 p.H2310P (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2299C	0.3952	167.0	0.0	0.0																									ROS1 p.S2299C (Missense)		LIHC_UNION	TCGA-DD-AACZ-01A-11D-A40R-10	TCGA-DD-AACZ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.L600*	0.56	75.0	0.0	0.0																									ROS1 p.L600* (Nonsense)		LIHC_UNION	TCGA-DD-A4NJ-01A-11D-A27I-10	TCGA-DD-A4NJ-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.S36*	0.5204	98.0	0.0	0.0																									ROS1 p.S36* (Nonsense)		LIHC_UNION	TCGA-CC-A8HS-01A-11D-A35Z-10	TCGA-CC-A8HS-10A-01D-A35Z-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.E582Q	0.4819	83.0	0.0	0.0																									PMS2 p.E582Q (Missense)		LIHC_UNION	TCGA-FV-A2QR-01A-11D-A20W-10	TCGA-FV-A2QR-11A-11D-A20W-10
Biologically Relevant				Somatic Variant	PMS2	Missense	p.N335D	0.378	164.0	0.0	0.0																									PMS2 p.N335D (Missense)		LIHC_UNION	TCGA-DD-AACP-01A-11D-A40R-10	TCGA-DD-AACP-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	POT1	Missense	p.L466F	0.1687	83.0	0.0	0.0																									POT1 p.L466F (Missense)		LIHC_UNION	TCGA-CC-A3MC-01A-11D-A22F-10	TCGA-CC-A3MC-10A-01D-A22F-10
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.Q574H	0.3261	46.0	0.0	0.0																									FGFR1 p.Q574H (Missense)		LIHC_UNION	TCGA-DD-AADL-01A-11D-A40R-10	TCGA-DD-AADL-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A491T	0.2101	119.0	0.0	0.0																									RUNX1T1 p.A491T (Missense)		LIHC_UNION	TCGA-DD-AAW3-01A-11D-A40P-10	TCGA-DD-AAW3-10A-01D-A40P-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.V456E	0.4375	32.0	0.0	0.0																									RUNX1T1 p.V456E (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S408N	0.3824	68.0	0.0	0.0																									RUNX1T1 p.S408N (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H309Q	0.1925	161.0	0.0	0.0																									RUNX1T1 p.H309Q (Missense)		LIHC_UNION	TCGA-NI-A8LF-01A-11D-A35Z-10	TCGA-NI-A8LF-10A-01D-A35Z-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P297L	0.3636	88.0	0.0	0.0																									RUNX1T1 p.P297L (Missense)		LIHC_UNION	TCGA-DD-AAVW-01A-11D-A40R-10	TCGA-DD-AAVW-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E171D	0.048	125.0	0.0	0.0																									RUNX1T1 p.E171D (Missense)		LIHC_UNION	TCGA-RC-A7SK-01A-11D-A34Z-10	TCGA-RC-A7SK-10A-01D-A34Z-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S105F	0.181	116.0	0.0	0.0																									RUNX1T1 p.S105F (Missense)		LIHC_UNION	TCGA-DD-AADO-01A-11D-A40R-10	TCGA-DD-AADO-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P101S	0.0642	109.0	0.0	0.0																									RUNX1T1 p.P101S (Missense)		LIHC_UNION	TCGA-K7-A5RF-01A-11D-A28X-10	TCGA-K7-A5RF-10B-01D-A28X-10
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.A78E	0.0571	70.0	0.0	0.0																									ESRP1 p.A78E (Missense)		LIHC_UNION	TCGA-DD-AADV-01A-11D-A38X-10	TCGA-DD-AADV-10A-01D-A38X-10
Biologically Relevant				Somatic Variant	ESRP1	Frameshift	p.R293Gfs*24	0.3138	239.0	0.0	0.0																									ESRP1 p.R293Gfs*24 (Frameshift)		LIHC_UNION	TCGA-G3-A5SK-01A-11D-A27I-10	TCGA-G3-A5SK-10A-01D-A27I-10
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E323G	0.3689	122.0	0.0	0.0																									ESRP1 p.E323G (Missense)		LIHC_UNION	TCGA-4R-AA8I-01A-11D-A382-10	TCGA-4R-AA8I-10B-01D-A385-10
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P545L	0.1682	107.0	0.0	0.0																									ESRP1 p.P545L (Missense)		LIHC_UNION	TCGA-DD-AAVQ-01A-11D-A40R-10	TCGA-DD-AAVQ-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	MYC	Missense	p.A165T	0.6842	38.0	0.0	0.0																									MYC p.A165T (Missense)		LIHC_UNION	TCGA-BC-A10Z-01A-11D-A12Z-10	TCGA-BC-A10Z-11A-11D-A12Z-10
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108G	0.3305	118.0	0.0	0.0																									CDKN2A p.D108G (Missense)		LIHC_UNION	TCGA-DD-AACK-01A-11D-A40R-10	TCGA-DD-AACK-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108Y	0.4016	127.0	0.0	0.0																									CDKN2A p.D108Y (Missense)		LIHC_UNION	TCGA-G3-AAV0-01A-11D-A36X-10	TCGA-G3-AAV0-10A-01D-A370-10
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.A86D	0.3182	132.0	0.0	0.0																									CDKN2A p.A86D (Missense)		LIHC_UNION	TCGA-DD-AAC9-01A-11D-A40R-10	TCGA-DD-AAC9-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D84Y	0.4021	97.0	0.0	0.0																									CDKN2A p.D84Y (Missense)		LIHC_UNION	TCGA-DD-AAD6-01A-11D-A40R-10	TCGA-DD-AAD6-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83D	0.5333	30.0	0.0	0.0																									CDKN2A p.H83D (Missense)		LIHC_UNION	TCGA-ED-A7XP-01A-11D-A34Z-10	TCGA-ED-A7XP-10A-01D-A34Z-10
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.S56R	0.4595	37.0	0.0	0.0																									CDKN2A p.S56R (Missense)		LIHC_UNION	TCGA-DD-AAW3-01A-11D-A40P-10	TCGA-DD-AAW3-10A-01D-A40P-10
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.3488	43.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		LIHC_UNION	TCGA-XR-A8TG-01A-11D-A35Z-10	TCGA-XR-A8TG-10A-01D-A35Z-10
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.N39Tfs*14	0.1905	42.0	0.0	0.0																									CDKN2A p.N39Tfs*14 (Frameshift)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.G23Rfs*27	0.3077	52.0	0.0	0.0																									CDKN2A p.G23Rfs*27 (Frameshift)		LIHC_UNION	TCGA-DD-AADG-01A-11D-A40R-10	TCGA-DD-AADG-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.T18Gfs*27	0.5532	47.0	0.0	0.0																									CDKN2A p.T18Gfs*27 (Frameshift)		LIHC_UNION	TCGA-DD-AAD8-01A-11D-A40R-10	TCGA-DD-AAD8-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.I159F	0.9123	171.0	0.0	0.0																									NTRK2 p.I159F (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.I159F	0.9108	157.0	0.0	0.0																									NTRK2 p.I159F (Missense)		LIHC_UNION	TCGA-UB-A7MB-01A-11D-A33Q-10	TCGA-UB-A7MB-10A-01D-A33Q-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.A268V	0.2769	130.0	0.0	0.0																									NTRK2 p.A268V (Missense)		LIHC_UNION	TCGA-EP-A2KA-01A-11D-A183-10	TCGA-EP-A2KA-10A-01D-A183-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.I330T	0.3333	138.0	0.0	0.0																									NTRK2 p.I330T (Missense)		LIHC_UNION	TCGA-CC-A7IE-01A-21D-A382-10	TCGA-CC-A7IE-10A-01D-A385-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.I417F	0.2545	165.0	0.0	0.0																									NTRK2 p.I417F (Missense)		LIHC_UNION	TCGA-ZP-A9CV-01A-11D-A382-10	TCGA-ZP-A9CV-10B-01D-A385-10
Biologically Relevant				Somatic Variant	NTRK2	Frameshift	p.E429Nfs*10	0.1321	159.0	0.0	0.0																									NTRK2 p.E429Nfs*10 (Frameshift)		LIHC_UNION	TCGA-DD-AADM-01A-11D-A40R-10	TCGA-DD-AADM-10A-01D-A40U-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.F730C	0.5188	133.0	0.0	0.0																									NTRK2 p.F730C (Missense)		LIHC_UNION	TCGA-ZS-A9CF-01A-11D-A382-10	TCGA-ZS-A9CF-10A-01D-A385-10
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.C765R	0.2353	68.0	0.0	0.0																									NTRK2 p.C765R (Missense)		LIHC_UNION	TCGA-ZP-A9CZ-01A-11D-A382-10	TCGA-ZP-A9CZ-10A-01D-A385-10
Biologically Relevant				Microsatellite Stability	Supporting variants		JAK1 p.I143Dfs*9 (Frameshift), POLE p.X1482_splice (Splice Site), MSH2 p.D864_C873delinsG (Deletion), MSH6 p.A53Gfs*23 (Frameshift), MSH6 p.K145* (Nonsense), ACVR2A p.X19_splice (Splice Site), ACVR2A p.R58Gfs*16 (Frameshift), ACVR2A p.Q124* (Nonsense), ACVR2A p.W207Kfs*34 (Frameshift), ACVR2A p.R255* (Nonsense), ACVR2A p.R438Efs*19 (Frameshift), ACVR2A p.M451Sfs*23 (Frameshift), ACVR2A p.R469_L470dup (Insertion), ACVR2A p.G473_C474del (Deletion), ACVR2A p.C474Yfs*26 (Frameshift), DOCK3 p.A1853Sfs*46 (Frameshift), ESRP1 p.R293Gfs*24 (Frameshift)																													Supporting variants: JAK1 p.I143Dfs*9 (Frameshift), POLE p.X1482_splice (Splice Site), MSH2 p.D864_C873delinsG (Deletion), MSH6 p.A53Gfs*23 (Frameshift), MSH6 p.K145* (Nonsense), ACVR2A p.X19_splice (Splice Site), ACVR2A p.R58Gfs*16 (Frameshift), ACVR2A p.Q124* (Nonsense), ACVR2A p.W207Kfs*34 (Frameshift), ACVR2A p.R255* (Nonsense), ACVR2A p.R438Efs*19 (Frameshift), ACVR2A p.M451Sfs*23 (Frameshift), ACVR2A p.R469_L470dup (Insertion), ACVR2A p.G473_C474del (Deletion), ACVR2A p.C474Yfs*26 (Frameshift), DOCK3 p.A1853Sfs*46 (Frameshift), ESRP1 p.R293Gfs*24 (Frameshift)		LIHC_UNION		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.504																													COSMIC Signature (version 2) 6 (50%)		LIHC_UNION		
Biologically Relevant				Mutational Signature	COSMIC Signature 19	version 2	0.432																													COSMIC Signature (version 2) 19 (43%)		LIHC_UNION		
